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While accessible by a relatively noninvasive blood draw, circulating tumor cells (CTCs) 
remain difficult to study because of their rarity and their presence amongst the billions of 
surrounding normal blood cells. Of particular promise and utility to the in-depth study of CTCs 
are those technologies making use of microfluidics and nanomaterials, such as the graphene oxide 
(GO) Chip. 
The GO Chip has been applied to a 41-patient metastatic castrate resistant prostate cancer 
(mCRPC) cohort. CTCs were enumerated from whole blood for all patients (range: 3-166 
CTCs/mL, median: 20 CTCs/mL). Clusters of CTCs, defined as two or more directly adjacent 
CTCs, were observed in 26/41 patients, and ranged in size from 2-8 CTCs/cluster. Within the CTC 
population, the percentage of CTCs present as clusters ranged from 0-54.8%. Additionally, a 
parallel device was run for 36 patients to ultimately obtain RNA to use in RT-qPCR to assess 
levels of 96 genes of interest. Enumeration and RNA expression data were compared with clinical 
outcomes including overall survival, radioclinical progression, and PSA progression. An eight-
gene score was determined to be highly prognostic of overall survival (AUC: 0.88), with the genes 
comprising the score suggesting the importance of a dedifferentiated expression phenotype in poor 
prognosis. 
Follow-up work in prostate cancer investigated the role of HER2 and EGFR in prostate 
cancer metastasis. Analysis of tissue microarrays showed HER2 expression in prostate cancer and 
bone metastases. Primary and secondary prostate sphere formation was dependent on high EGFR 
Abstract 
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expression as determined by FACS, but not on HER2 expression. EGFR was also implicated in 
survival in transit as shown by the presence of EGFR+ CTCs isolated by the GO Chip in 9/10 
mCRPC patients assays, with an average of 35.5% of CTCs showing EGFR expression. Dual 
inhibition of HER2 and EGFR in mouse xenograft models prevented tumor growth. 
HER2 and EGFR as well as ADAM15 and CD31 were studied in bladder cancer CTCs as 
well. In a preliminary study primarily for optimization, antibodies were chosen for higher 
sensitivity capture as well as to stain bladder CTCs for the markers of interest. Ultimately, CTCs 
were isolated from five metastatic bladder cancer patients (range: 5-499 CTCs/mL), and a 
combination of staining antibodies that showed low background in the healthy control was chosen. 
EGFR+ and CD31+ CTCs were observed, while HER+ and ADAM15+ CTCs were not, and 
clusters of CTCs were isolated from some patients. 
To address drawbacks in the current technology, two strategies were attempted to enable 
cell release. A layer-by-layer (LbL) substrate enclosed in a microfluidic chamber featured different 
disadvantages based on film composition, but a thermosensitive polymer substrate enable release 
when cooled below its lower critical solution temperature of 12-13°C. The polymer-GO composite 
showed between 84.9 and 95.2% capture efficiency of EpCAM expressing cell lines and released 
over 91% of cells captured from whole blood. Using this device, CTCs were captured from 2/3 
pancreatic cancer patients and 8/10 breast cancer patients. FISH for HER2 was performed on CTCs 
isolated from one breast cancer patient. 
With high performing technologies to separate them from the noise of other cells in the 
blood, CTCs can provide information about disease spread in genitourinary cancers. The future 
incorporation of CTC-related information into clinical decision making has the potential to better 
inform treatment selection and disease prognosis. 
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1.1 Metastasis 
An intimidating aspect of cancer is its ability to spread, with metastasis causing 90% of 
cancer-related deaths (2, 5). Metastasis is a multistep process in which tumor cells escape from the 
primary tumor site, enter the bloodstream, arrest at a secondary site, extravasate, and proliferate to 
form secondary tumor colonies (Figure 1-1) (6, 7). To migrate through the primary tissue and 
intravasate into the blood, the cell experiences several changes. Increased mobility and the loss of 
adhesive proteins allow the cell to traverse the extracellular matrix components and the basement 
membrane in its initial location (2, 8-10). Many of these transformations are characteristic of the 
epithelial-mesenchymal transition (EMT), a process normally seen in embryogenesis that allows 
cancer cells to gain the motile phenotype coupled with the loss of distinguishing epithelial markers 
(11-13). The cell persists through phenotypic refinement, but without interaction with its 
environment, it would be unable to progress. An aggressive tumor cell is able to fight impediments 
to intravasation posed by the microenvironment such as hypoxia and an immune response using 
the tools at hand: stromal cells and their secreted factors are hijacked into both helping the tumor 
cell enter the blood stream as well as prepare the secondary environment for colonization (2). 
Similarly, once the tumor cell has left the primary environment and entered the blood, it can 
aggregate with platelets to avert the immune response and gain protection from the shear stress 
caused by fluid flow. But arrival at the secondary microenvironment does not guarantee 
proliferation as the cell may remain dormant or even die (6). Only a small percentage of these 
Chapter 1 Introduction 
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tumor cells will ultimately grow into micrometastases, and of those micrometastases few still will 
proceed into full blown macrometastatic lesions. This process occurs in parallel to the development 
of the primary tumor, and often before that tumor is initially detected (14). Very few of the initially 
disseminated cells complete the metastatic process (15), and yet it is these few cells lead that 
charge of cancer mortality. To be able to isolate and identify these cells is a clear direction of 
interest in cancer research (16, 17). 
 
1.2 Circulating tumor cells (CTCs) 
The ease of drawing blood coupled with the wealth of potential information about 
metastatic mechanisms make circulating tumor cells (CTCs) a tantalizing target for study, 
particularly given their clinical relevance. Several studies correlate CTC counts with various 
clinical time points including overall survival and progression free survival. Most of these studies 
set discrete cut-offs and have evaluated the associations within cohorts in cancers such as breast 
(18-20), colorectal (21-23), prostate (24), and melanoma (25). In some cases, these cut-offs have 
Figure 1-1 Schematic view of the metastatic process showing CTC transit: the CTCs exit the primary tumor, intravasate into the 
blood stream, circulate, and extravasate into a secondary site where they may ultimately achieve different fates including dormancy 
and full-blown metastasis. 
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been shown to better predict overall survival than traditional biomarkers such as the prostate 
specific antigen (PSA) (24). However, while CTCs have been used in American Society of Clinical 
Oncology (ASCO) recommendations (26), more widespread use of CTCs as prognostic indicators 
is hindered by the lack of Stage III clinical data (27). Difficulties in including CTCs as potential 
biomarkers in clinical trials include the low number of CTCs recovered (hindering downstream 
analysis), the inconsistent biological and molecular characterization of CTCs, and questions 
regarding the usefulness of CTC enumeration (28). Other open questions involve the nature of 
these spreading cells: do they travel as individual cells or as clusters (29). However, to address 
concerns regarding the use of CTCs, they first must be isolated for study. 
1.3 CTC isolation technologies 
To facilitate enumeration and isolation, various devices and technologies have been 
developed to capture CTCs. However, their operating principles are often at odds with 
heterogeneous and metaphoric nature of the cells of interest. While all technologies are broadly 
based in the principle of separating based on how CTCs differ from surrounding blood cells, be it 
in their surface marker expression or their relative size, each technology features advantages and 
drawbacks. On-going research in CTC isolation technologies seeks to address these downsides. 
1.3.1 Commercially available CTC isolation technologies 
1.3.1.1 FDA Approved Cell Search CTC Isolation Technology 
 Although tremendous progress has been made in the field of CTC isolation techniques in 
the past two decades, there are very few technologies that are commercially available for clinical 
and research use. One example is the CellSearchTM system (Veridex LLC), which was the first US 
Food and Drug Administration (FDA) approved system for the detection and enumeration of CTCs 
in metastatic breast (30), prostate (31), and colon cancer patients (22). Using magnetic beads 
 4 
 
coated with antibodies against the epithelial cellular adhesion molecule (EpCAM), CellSearchTM 
isolated CTCs from the peripheral blood, after which they were fixed with 4% paraformaldehyde 
(PFA), immunostained with fluorescently labeled anti-cytokeratin (CK, an epithelial intermediate 
filament), anti-CD45 (a membrane antigen expressed by leucocytes), and DAPI (4’,6-diamidino-
2-phenylindole, a nuclear stain), and enumerated by automated cell image capture and analysis. 
Cells designated as CTCs were characterized by low eccentricity, size greater than 5 µm, a visible 
nucleus, positive staining for CK, and negative staining for CD45. To verify the accuracy, 
precision, and linearity of the CellSearchTM system, Allard et al. evaluated the number of CTCs 
per 7.5 mL of blood using spiked samples as well as in 145 healthy donors, 199 patients with 
nonmalignant diseases, and 964 patients with various types of metastatic carcinomas (32). The 
average recovery of SKBR-3 tumor cells spiked into 7.5 mL of blood was 85%. In blood samples 
from cancer patients, between 0 to 23,618 CTCs were recovered per 7.5 mL, with 36% of 
specimens yielding at least 2 CTCs. 
 CellSearchTM has been widely applied to the study of prostate cancer CTCs, though the 
numbers of CTCs isolated remains relatively low. In a study of 63 metastatic castrate resistant 
prostate cancer (mCRPC) patients (33), a median of 16 CTCs were isolated per 7.5 mL blood 
(range: 0-847 CTCs/7.5 mL) with 65% of patients having greater than 5 CTCs/7.5 mL This study 
also examined androgen receptor (AR) amplification through fluorescence in situ hybridization 
(FISH) and saw this amplification in five samples, all of which had over 50 CTCs/7.5 mL. Further 
immunofluorescence analysis detected EGFR in 18 of 20 assayed patients. Another study 
examined 120 CRPC patients with the CellSearch system, with 112 patients having “evaluable” 
CTC counts (median: 9 CTCs/7.5 mL), and found that baseline CTC counts were strongly 
associated with survival from the time of blood draw (34). There have been a number of subsequent 
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studies investigating the stratification into favorable and unfavorable categories (24); AR and 
MYC amplification (35); AR, ERG, and PTEN amplification, rearrangement, and loss (36); 
potential for use as a surrogate biomarker (37); and change in response to treatment (38). 
While the CellSearchTM system represented a breakthrough in CTC separation technology 
both in principles and in clinical applications, it is not without room for improvement. Given the 
rarity of CTCs, higher recovery and sensitivity would be desirable for most applications. 
Additionally, increased purity and the isolation of viable cells would allow more downstream 
analysis that could be informative for the study of cancer biology and for use in personalized 
medicine. The system itself requires expensive equipment. This technology represents an 
innovative milestone in CTC research, but it is a platform upon which the body of literature can 
build.  
1.3.1.2 Size Based Filtration Techniques 
 Based on his observation that tumor cells in the blood were often larger than other blood 
components such as erythrocytes, leukocytes, and platelets, Seal first used a simple sieve as a filter 
to separate what are now known as CTCs from the blood in 1964 (39). Isolation by Size of 
Epithelial Tumor Cells (ISET), a filtration technique commercially available as the Rarecells 
system®, was an improvement over previous filtration methods as it did not require a preliminary 
separation through techniques such as immunomagnetic and flow cytometric cell separation (40). 
Following dilution of the blood sample, the CTCs could be separated from the solution using a 
Track-Etch polycarbonate membrane with 8 μm diameter cylindrical pores. To characterize ISET, 
cells from liver, breast, cervical, and prostate cancer cell lines (HepG2, Hep3B, MCF-7, HeLa, 
and LNCaP) were spiked into 1 mL of peripheral blood. Captured cells could then undergo genetic 
analyses such as fluorescence in situ hybridization (FISH) and the polymerase chain reaction 
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(PCR). Efficacy of the system was further assessed using samples from primary liver cancer 
patients, with CTCs found in 23 of the 44 patients and none of the healthy control subjects (41). 
Cells were classified as CTCs based on size, nucleus to cytoplasm area ratio, and nuclear 
irregularities. Primer extension pre-amplification (PEP) and PCR were performed on the separated 
tumor cells as proof of ISET’s applicability in cancer study. 
Modifications to the filtration process are an area of continuing research, with advances 
being made in both the materials used and their fabrication (discussed below). This further 
optimizes a technique that allows viable cell separation for staining and morphological observation 
as well as an immediate platform for cell culture. However, most filtration methods are still 
plagued by inconvenient preprocessing steps such as dilutions, flow cytometry, and 
immunomagnetic separation, which also affect overall throughput. Membrane clogging can result 
in issues with purity, while variability in CTC size can lead to the loss of these rare cells. 
1.3.1.3 Other commercially available systems 
The Epic Platform makes use of high throughput imaging based analysis without 
enrichment from surrounding white blood cells. To prepare samples using the Epic Platform, 
samples undergo red blood cell lysis and centrifugation, after which the entirety of the resulting 
supernatant is mounted on a series of slides. These slides may be stained for standard CTC makers, 
i.e. cytokeratin, CD45, and DAPI. The slides are then fluorescently scanned and analyzed using 
an algorithm that assesses fluorescence levels and morphology to identify CTCs. This method 
detected CTCs in 39 out of 46 mCRPC samples during validation (42). Subsequent studies 
investigated the presence of the AR splice variant AR-V7 in a cohort of 161 patients (43) and AR 
expression, PTEN deletion, and ERG rearrangement (44). This last study also detected clusters in 
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7/41 patients. Due to the high contamination by white blood cells and the preparation of the 
samples as slides, studies performed using this technology are limited to imaging based analysis. 
1.3.2 Microfluidic CTC isolation technologies 
Microfluidic devices provide innovative solutions to logistical problems, affording the 
advantages of high sensitivity, low cost, low reagent usage, small size, and several established 
fabrication techniques (45). Operating on this length scale allows for laminar flow, yielding 
parallel streamlines with minimal mixing resulting only from diffusion (46). In general, these labs-
on-a-chip or micro total analysis systems (μTAS) consist of several elements from the microfluidic 
tool box including pumps, valves, reservoirs, and mixers, in addition to other thermal and electrical 
components (47). Devices are often constructed from glass or silicon substrates, however the low 
expense and plethora of simple fabrication methods have led to the development of a number of 
polymer-based devices (46). PDMS (polydimethylsiloxane) in particular has emerged as a 
fundamental material in microfluidics, facilitating inexpensive prototyping (48). Arising from an 
array of small scale analytical techniques (45), an early biological application of microfluidics was 
a device that performed PCR, improving upon large-scale methods by decreasing the time of each 
step (49). Other applications include on-chip molecular separation, protein analysis, 
immunosensing, and electronics cooling (50). Given the many benefits of microfluidics, including 
a length scale amenable to cellular analysis, it is unsurprising that microfluidic devices are a staple 
in CTC isolation and analysis (Figure 1-2). 
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1.3.2.1 Microscale CTC isolation based on physical properties 
CTCs also differ from blood cells in size and deformability, offering molecular marker-
independent, high-throughput, and inexpensive options for isolation. CTCs are generally larger 
and stiffer than WBCs, leading to the early use of commercial filters (51, 52). To solve problems 
with earlier filters including fixation requirements, non-uniform pore sizes, and low pore density, 
the separable bilayer (SB) microfilter was microfabricated by etching parylene polymer via 
reactive ion etching to precisely control pore sizes and density (53). Parylene is ideal for this 
application because it is mechanically strong while still malleable, with good biocompatibility and 
low membrane fouling. The bilayer design consisted of a bottom layer with 8 μm pores and a top 
Figure 1-2 Microfluidic CTC isolation technologies. Examples of antigen based (immunocapture) and physical property based 
separation in microfluidic systems. Percentages denote capture efficiency as determined through cell line optimization. (1, 2) 
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layer with 40 μm pores, trapping CTCs between the two layers that could be separated easily, 
leaving CTCs accessible. A flexible micro spring array (FMSA) was designed as a high-porosity 
filter (54) capable of processing 7.5 mL whole blood without clogging while still preserving 
viability. CTCs were detected in 76% of clinical samples from breast, colorectal, and lung cancer 
patients. Microclusters and multinucleated CTCs were enriched from patients from all three 
cancers. 
An alternative approach to separation exploited unique properties of particles moving in 
microchannels. Under laminar flow, deterministic lateral displacement (DLD) within an array of 
microposts has been used to separate particles of different sizes (55). Depending on the geometry 
of the microarrays, particles above and below a certain size follow different and predetermined 
migration paths. The CTC-iChip utilized DLD to first separate nucleated cells (CTCs and WBCs) 
from red blood cells (RBCs) using an array of microposts with 32-μm gaps (56). When flowing 
through the device, small cells like RBCs remained along their original streamlines, whereas larger 
cells like CTCs and most WBCs were fully deflected into the coincident running buffer stream by 
the end of the array.  
Other separation approaches exploited inertial forces. Within microchannels, particles of 
different sizes can migrate across streamlines to focus at different positions due to the shear 
induced lift force and the wall induced lift force. In vortex technology, cells of various sizes are 
aligned by size in different streamlines in straight channels by inertial focusing followed by 
multiple expansion-contraction reservoirs to create laminar microvortices that can trap large cells 
within reservoirs (57). As cells entered the expanding regions, wall lift forces were diminished and 
cells mainly experienced lateral lift forces, which are proportional to the cell volume. The larger 
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lift forces on CTCs pulled them into the vortices while other blood cells experiencing smaller 
forces passed through the vortex and remained in the main stream. 
Curvature in microchannels causes particles to experience an additional lateral Dean drag 
force because fluids in curved channels develop a secondary lateral flow. The combination of the 
inertial lift force and the Dean force leads to particle migration which can result in high resolution 
separation. Single spiral, double spiral, cascaded spiral, and slanted spiral structures have been 
designed and optimized to maximize separation efficiency for various parameters including 
channel length, height, width, radius of curvature, and flow rate (58-61). Generally, near the outlet 
of spiral devices, larger CTCs focus near the inner wall due to the combination of the inertial lift 
force and the Dean drag force. To this end, Hou et al. designed a multiplexed spiral device that 
detected CTCs in clinical samples from breast and lung cancer patients (62). 
CTC enrichment by size offers a fast, inexpensive, and label-free way to harvest CTCs. 
However, as there is a wide range of CTCs sizes, sized based separation often suffers from low 
purity and the risk of losing smaller CTCs. Additionally, size based separation often requires 
preprocessing of blood, like RBCs removal and further, dilution or runs the risk of device clogging. 
To date, size based technologies have shown proof-of-concept clinical validation but have not been 
applied in large scale clinical or biological investigation. 
Other separation methods based on physical properties include the interplay of 
dielectrophoresis (DEP) forces and inertial forces in microfluidic devices to lead to different 
patterns of cell migration to viably separate cells (63). Similarly, acoustophoresis causes particles 
within the fluid to move toward regions with minimal acoustic radiation forces in distinct 
migration patterns (64, 65). Although promising, approaches like DEP and acoustophoresis have 
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the disadvantages of low throughput, low sensitivity and purity, and additional required steps like 
RBC lysis and may require further clinical validation.  
1.3.2.2 Microfluidic immunoaffinity based CTC isolation 
 The alternative to separation of CTCs based on size is their separation based on cell surface 
marker expression. Nagrath et al. pioneered a silicon-based microfluidic device for the 
immunocapture of CTCs from cancer patient blood samples (66). This device featured viable cell 
isolation in addition to lacking sample preprocessing steps. The CTC-chip had an array of 78,000 
silicon microposts which were subsequently coated with anti-EpCAM capture antibodies. The 
optimal flow rate was determined to be 1-2 mL/hr in order to maximize the capture efficiency, 
which was greater than 60% for the NCI-H1650 cells spiked into whole blood. As the normalized 
number of CTCs recovered from the blood has been correlated with efficacy of treatment (67), 
demonstrating an emerging clinical significance of the enumeration of CTCs, CTCs were 
enumerated in samples from 68 patients with non-small-cell lung (n=55), prostate (n=26), 
pancreatic (n=15), breast (n=10), and colon (n=10) cancers. Using fluorescent staining, CTCs were 
identified as those stained cells with DAPI+/CK+/CD45-, and were detected in 115 of 116 (99%) 
samples. While the number of CTCs in a patient sample did not reflect the size of the primary 
tumor, it did correspond to the patient’s response to treatment. Because of its high yield, sensitivity, 
specificity, and clinical relevance, this chip represented great strides in the field of CTC isolation. 
The research team went on to show further clinical applications using the Scorpion Amplification 
Refractory Mutation System (SARMS) technology to identify the T790M mutation in the 
epidermal growth factor receptor (EGFR) (68). This mutation is associated with tumor resistance 
to tyrosine kinase inhibitors, and the data gained from this study could potentially be used to 
determine the appropriate course of treatment. Using the CTC-chip, CTCs were isolated from non-
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small-cell lung cancer patient samples for analysis and compared with results from the primary 
tumor as well as free plasma DNA. The mutation was found in the CTCs of 11 of 12 patients 
whose primary tumors featured this mutation and the free plasma DNA of 4 out of these 12 
patients. Increased CTC counts were correlated with tumor progression and further EGFR 
mutations. This demonstrated the utility of an immunocapture micropost device in a noninvasive 
genotyping procedure. 
In addition to the circular posts used by Nagrath et al., microposts on silicon chips have 
been designed to optimize capture through the manipulation of streamlines using alternative post 
geometries. Termed geometrically enhanced differential immunocapture (GEDI) (69), octagonal 
posts were staggered to maximize collisions with cells. The immunocapture aspect was achieved 
with a monoclonal antibody against the prostate-specific membrane antigen (PSMA), J591, and as 
such, the device was characterized with the LNCaP prostate cancer cell line. Applications of this 
device were demonstrated by performing capture with prostate cancer patient samples, as well as 
proof-of-principle ex vivo drug testing using the taxanes docetaxel and paclitaxel (70). The device 
has been additionally functionalized with antibodies against HER2 to capture cancer cells known 
to have this membrane receptor upregulated (71). Following the selection of the most optimal anti-
HER2 antibody, the device was characterized with high and low HER2-expressing breast cancer 
cell lines, yielding capture efficiencies of 78% and 26% respectively. Clinical efficacy was verified 
through the analysis of nine blood samples from five breast cancer patients and two gastric cancer 
patients with an average of 74 CTCs/mL identified in breast cancer patients and 120 CTCs/mL in 
gastric cancer patients. 
In another example of silicon structures, pillars were deep reactive ion etched into a silicon 
wafer to form a capture surface which was then anodically bonded to glass wafer patterned with 
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microfluidic chambers, a capture and recovery chip (CRC) (72). This CRC was functionalized 
with streptavidin to capture cells pretreated with hybrid nanoparticles (HNPs) consisting of an 
antibody, a quantum dot, and biotinylated DNA, which bound to the avidin on the surface. Three 
different HNPs were prepared, each with a different antibody (anti-EpCAM, anti-EGFR, or 
HER2), quantum dot (Qdot(525 nm), Qdot(565 nm), or Qdot(625 nm)), and DNA sequence, 
allowing the specific marking and release of different breast cancer cell lines. Respective quantum 
dot fluorescence ratios were reflective of established cell line expression patterns, and cell spike 
experiments using whole blood yielded capture efficiencies of 81.3%, 91.2%, and 90.0% for the 
cell lines MCF-7, SKBR-3, and MDA-MB-231, with identification accuracies of 94.7%, 99.3%, 
and 83.3% based off said fluorescence patterns. Using restriction enzymes, cells were released into 
96-well plates with efficiencies of 78.6%, 93.7%, and 86.0%, where they were able to adhere and 
proliferate. 
In contrast to the silicon based substrate used with the original CTC-chip, glass is an 
attractive substrate for CTC capture chips due to its transparency for clear imaging, allowing for a 
wide variety of light microscopy based techniques yielding both bright field and fluorescent 
images. Shortly after the advent of the CTC-chip, the Toner group released a herringbone CTC 
capture chip that made use of passive mixing to increase encounters between flowing cells and 
anti-EpCAM-functionalized PDMS microchannels (73). The creation of microvortices was 
induced in this “Herringbone-chip” through chevron patterns on a PDMS ceiling, disrupting 
streamlines and increasing the capture efficiency. Once tethered to the chip through the antibody-
antigen interaction, cells could be stained for DAPI, CK, and CD45. The capture efficiency for 
prostate cancer cells (PC-3) spiked into whole blood was 91.8%, with 14% purity and 95% 
viability. The device was further tested with metastatic prostate cancer patient samples, with 93% 
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detection rate. The optical transparency of the glass allowed for further analysis in the form of 
fluorescence in situ hybridization (FISH) to determine androgen receptor copy number in LNCaP 
cells. Off-chip analysis included RNA isolation for real-time PCR (RT-PCR), allowing the 
identification of a specific TMPRSS2-ERG translocation. The utility of the Herringbone-chip was 
demonstrated through its use in a study of the epithelial-mesenchymal transition (EMT) in breast 
cancer CTCs (74). Using multiple capture antibodies, anti-EpCAM, anti-EGFR, and anti-HER2, 
CTCs were isolated and subjected to RNA in situ hybridization, showing the presence of 
mesenchymal marker-displaying CTC clusters as well as the epithelial to mesenchymal spectrum 
of CTCs. 
 Herringbone micromixers have been optimized in a geometrically enhanced mixing (GEM) 
chip to increase throughput and purity in anti-EpCAM immunocapture (75). By increasing the 
width of the grooves within the micromixer, purity was increased to 84% for pancreatic cell line 
(L3.6pl) cells spiked into whole blood. However, a high number of white blood cells were present 
when patient samples were analyzed, leaving room for additional optimization. As CTCs were 
detected in 17 of 18 patients studied, and CTC number corresponded to tumor size in three stage 
IV metastatic pancreatic cancer patients analyzed over the course of treatment, this technology 
appears to hold promise for use in the clinical setting. 
Another device from the Toner group, the CTC-iChip, took advantage of multiple modes 
of separation (56). Samples were labeled with magnetic beads before introduction to the chip, at 
which point running buffer diluted the sample while performing initial separation based on cell 
size. Remaining cells were then aligned using a focusing channel for ultimate magnetic separation. 
The device could be operated in either positive or negative selection mode based on the choice of 
antibody conjugated to the magnetic bead. Positive selection was performed using beads with 
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antibodies to select CTCs, while negative selection selected for white blood cells, leaving all 
unlabeled cells for further analysis. Isolated cells could undergo a wide spectrum of analysis 
including immunofluorescence, hematoxylin and eosin, and Pap staining; FISH; and gene 
expression analysis. Over the course of the study, patient samples were processed from breast, 
lung, prostate, pancreatic, colorectal, and melanoma cancers. 
The VerIFAST system (76) is another magnetic bead-based microfluidic technology that 
was designed with an emphasis on practical operation. Following incubation with antibody 
conjugated paramagnetic particles, magnetically labeled cells could then be dragged through oil 
pinning wells using a handheld magnet, bringing target cells through to the next stage while blood 
cells remained in the input well. Following incubation in the staining well, the cells could be moved 
to a sieve well where magnetic particles were removed and any intracellular staining was 
conducted. This technique was applied to blood and lavage samples, allowing staining for TTF-1 
and EGFR. While limited to staining applications, the VerIFAST used immunomagnetic 
separation and the lack of interaction between oil and aqueous solutions to streamline the capture 
and staining process. This technology has since been updated, renamed, and applied to 26 prostate 
cancer patient samples (77), detecting CTCs in 25/26 patients (range: 0-1213 CTCs/7.5 mL blood). 
RT-qPCR was performed for 12 genes, and androgen receptor splice variants were detected. 
Poly(methyl methacrylate) (PMMA) can serve as an alternative to silicon or polystyrene 
as a substrate for microfluidic CTC capture and analysis devices due to its low cost and excellent 
optical transparency. Polymers such as PMMA are advantageous due to their amenability to 
convenient fabrication techniques such as hot embossing and injection molding. Carboxylic acid 
groups can be selectively generated on the surfaces of PMMA by UV exposure to explore 
electroless deposition, protein concentration, and cancer cell capture (78). Increased roughness can 
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be induced using high intensity light, providing increased surface area for functionalization. 
Additionally, thermal bonding occurs at low enough temperatures to preserve these microfeatures 
(79). Using these properties of PMMA, a high throughput microsampling unit (HTMSU) was 
developed. The HTMSU was functionalized with anti-EpCAM monoclonal antibodies for capture 
and included a conductivity sensor which enabled enumeration. The device was initially 
characterized with MCF-7, SW620, and HT29 cells (breast and two colorectal cell lines, 
respectively), showing the potential for cell release via trypsin and cell analysis using the 
polymerase chain reaction (PCR) and ligase detection reaction (LDR) (79, 80). The benefits of the 
high aspect ratio features of PMMA are not limited to antibody capture. The anti-EpCAM 
monoclonal antibodies were exchanged for RNA aptamers against the prostate-specific membrane 
antigen (PSMA) for tissue-specific recognition (80). 
Cyclic olefin copolymer (COC) has the advantages of PMMA in addition to having 
increased optical transmissivity; the implication of this is increased UV activation-produced 
carboxyl groups for increased capture antibody presentation, yielding higher capture efficiencies 
and purities (81). This polymer was used as the substrate for a high throughput (HT) CTC selection 
module that comprises a component of a CTC isolation and analysis system (82). Following 
capture in high aspect ratio sinusoidal anti-EpCAM functionalized microchannels, CTCs were 
released using trypsin. The cells flowed across an impedance sensor embedded in PMMA for 
enumeration into a 2D array fabricated in PMMA for staining and confined imaging. The capture 
efficiency for the selection module was dependent on channel length, with an overall average of 
83.1% and a maximum of greater than 90%. Collection efficiency of the staining and imaging 
module was determined by comparing stained cells with numbers generated by the impedance 
sensor. Fixed cells were collected with higher efficiency than unfixed cells (96% vs. 85%). A lower 
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collection efficiency of 72% was exhibited by analyzed pancreatic ductal adenocarcinoma (PDAC) 
patient samples, possibly a result of the 15% misclassification rate inherent in the impedance 
sensor due to the enumeration of white blood cells. Samples analyzed from metastatic and local 
PDAC patients averaged 53 and 11 CTCs/mL respectively with a high purity of 86%, although 
cell viability was negatively affected by trypsinization. 
 The integration of microfluidics represents a dramatic change in the CTC separation 
paradigm, allowing for increased purity, yield, and sensitivity when compared to the CellSearchTM 
system. However, in the interest of increasing these metrics, researchers have increasingly turned 
to the incorporation of nanomaterials in addition to the use of microfluidics. Through interaction 
on the scale of extracellular structures, increased capture agent presentations, and the ability to 
transition to capture agent independent methods, nanomaterials provide the advantages necessary 
to take these next steps in CTC research.  
1.3.3 CTC Devices Incorporating Nanomaterials 
1.3.3.1 Magnetic Nanoparticles 
 Magnetic nanoparticles (MNPs) can be used to take advantage of surface expression as 
well as innate physical properties of the cell. Following the exchange of blood plasma for dilution 
buffer, MNPs functionalized with anti-EpCAM were used to bind selected cells in the presence of 
a magnetic field in a reversibly bonded PDMS chamber using NdFeB block magnets (83). The 
PDMS was then removed, facilitating microscopy. Cells were stained for CK, CD45, and DAPI 
and evaluated using computer automation with 90% capture ratios observed for spiked cell lines. 
An additional example of immunomagnetic separation included a dynamic set-up to minimize cell 
aggregation and settling while maximizing capture (84). Using a magnet which was positioned in 
direct contact with the microchannel (with the exception of the inlet, preventing accumulation), 
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cells labeled with Fe3O4 MNPs were separated in up to six devices that were rocked and 
repositioned during flow. Staining was performed with DAPI, anti-CK, and anti-CD45. 
Characterization with Colo205, PC-3, and SKBR-3 cell lines yielded 97%, 107%, and 94% capture 
ratios. Devices tested with patient samples showed comparable results to portions of those same 
samples exported to CellSearchTM for comparison.  Like the Herringbone-chip, cell clusters were 
found. 
The inherent properties of the MNPs themselves have been exploited to characterize CTCs. 
Through the immunolabeling of three different sizes (10, 12, and 16 nm) of MNP with various 
biomarkers, a cell expressing those biomarkers can in turn be labeled with these MNP complexes 
(85). Levels of expression can be detected due to the directly proportional relationship between 
the magnetic moment of the targeted cell and the number of bound MNPs. Biomarker expression 
was determined by the magnetization curve representative of the different MNP sizes. Using a 
micro-Hall detector to detect the magnetic moments of cells in a solution, Issadore et al. counted 
CTCs from patient blood. MNP-complex-labeled cell solutions were processed through a 
microchannel array featuring a chevron ceiling, focusing the cells toward the bottom center of the 
channel over the implanted micro-Hall detectors. The four biomarkers (HER2/neu, EGFR, 
EpCAM, and mucin-1) detected CTCs in all 20 ovarian cancer patients whereas CellSearchTM 
performed on samples from those same patients only found CTCs in five. This same four-
biomarker panel was used with a novel bioorthogonal nanoparticle detection (BOND) strategy to 
amplify cell labeling by immunolabeled MNP, to allow detection by a micro-nuclear magnetic 
resonance (µNMR) platform, as described in a recent review (86). 
Separation of CTCs from the blood through use of immunomagnetic nanobeads was 
achieved through lateral magnetophoresis, allowing for high throughput and purity (87). 
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Microchannels were molded in SU-8 photoresist above ferromagnetic wires. Pre-immunomagnetic 
nanobead labeled blood and buffer were introduced in two separate inlets and converged in the 
main channel, flowing above the wire-containing substrate. The application of a magnetic field 
drew the labeled cells into a separate smaller outlet from the larger outlet into which the blood 
cells naturally flowed due to the laminar nature of the channels. This setup led to 90% recovery in 
cell spike solutions and an average of 85% and 83% purities for 3 breast and 3 lung cancer patient 
samples respectively. Downstream analysis was demonstrated through the RT-PCR detection of 
thyroid transcription factor-1 (TTF-1) expression levels in the isolated cells. 
MNPs were also strategically self-assembled for use in CTC capture, detection, and 
downstream analysis (88). Layer-by-layer assembly was used to coat nanospheres with alternating 
layers of poly(ethylene imine) and MNPs. A series of reactions ultimately presented carboxylic 
acid groups on the surface of the magnetic nanospheres, allowing for NHS/EDC chemistry to be 
used for functionalization with anti-EpCAM. Characterization with 100 cells/mL spiked into 
whole blood of EpCAM-expressing cell lines showed capture efficiencies of greater that 92%. 
90.5% of captured cells were viable and could be cultured in vitro. CK19 and EGFR mutations 
could be detected through RT-PCR. Varied volumes of blood samples from patients with colon, 
liver, lung, and breast cancer patients were analyzed, with CTCs being detected in all. 
 Immunomagnetic labeling was combined with a magnetic sifter for high throughput (10 
mL/hr) cell capture and subsequent release (89). In the presence of a magnet, samples prelabeled 
with anti-EpCAM-conjugated MNPs were drawn to the edge of the 40 µm pores in a silicon nitride 
membrane that was coated with an 80% nickel 20% iron permalloy; unlabeled cells continued 
through. Release occurred following the removal of the magnet and a buffer wash, releasing 92.7% 
of captured cells. Between 31 and 96 CTCs/mL were detected in each of six non-small-cell lung 
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cancer patients. Using antibodies specific to wild type and mutated EGFR, additional analysis 
could be performed by applying extracted membrane proteins to a magneto-nanosensor biochip. 
Using genetic engineering techniques, Maeda et al. were able to harness the cellular 
machinery of the bacterium Magnetospirillum magneticum AMB-1 to modify its naturally-
produced nanoscale bacterial magnetic particles (BacMPs) (90). The BacMPs were enclosed in a 
membrane which has a number of integral proteins that can be used in gene fusion to effectively 
conjugate a desired protein to the BacMP. Maeda et al. fused the biotin carboxyl carrier protein 
(BCCP) as well as Protein G to the bacterial protein Mms13. Streptavidin conjugated with a 
quantum dot bound the expressed biotin, functionalizing the particle for imaging. To perform cell 
capture, the solution of interest was incubated with an anti-EpCAM antibody followed by mixing 
with the nanocomposite, which bound the constant fragment of the antibody with the fused Protein 
G. A magnetic separation was performed, yielding 92% recovery in experiments using cell lines. 
 As shown by these examples, the nanoscale affords a breadth of advantages not available 
to traditional magnetic methods. Cellular internalization, signature size-based characteristic 
magnetic curves, and natural production and scale-up are several features that can be exploited by 
operating in the nano regime. 
1.3.3.2 Nanopillars, Nanowires, and Nanofibers 
 The ability of cell surface components to interact with nanofeatures due to their mutual 
scale is a fundamental asset in the biological application of nanotechnology (91). The fabrication 
of such elements for cell capture has been performed using multiple materials in several structures. 
   Silicon was etched or deposited into nanopillars or nanowires to increase surface contact 
with extracellular features. Wang et al. used a silver and hydrofluoric acid etching process to create 
a surface of silicon nanopillars (SiNP). After attaching streptavidin through NHS/maleimide 
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chemistry, biotinylated anti-EpCAM was coupled, joining the capture antibody to the SiNP (92). 
The capture efficiency of SiNP modified substrates (45-65%) was up to ten times higher than that 
of the flat silicon substrates (4-14%). The effect of SiNP length on capture was tested, resulting in 
speculation that the optimized lengths corresponded to lengths amenable to interaction with 
extracellular structures. Having optimized the substrate with MCF-7 cells spiked into whole blood, 
a SiNP surface was used in conjunction with a chaotic micromixer for both cell line and patient 
sample CTC capture (93). The results from patient sampling were compared with CellSearchTM 
analysis, and showed a marked improvement over this established method, detecting CTCs in 20 
out of 26 patients while CellSearchTM found CTCs in only 8 of those patients. Using a chemically-
etched silicon nanostructured surface with similar dimensions under the name silicon nanowires 
(SiNW), Hou et al. were able to conjugate a temperature sensitive polymer, poly (N-
isopropylacrylamide) (PIPAAm), to the high surface area substrate, designated SiNWS, allowing 
for controlled release of captured CTCs (94). Further conjugated with anti-EpCAM antibodies, the 
functionalized SiNWS-bound PIPAAm facilitated cell capture at a ratio of over 70% of labeled 
MCF-7 cells spiked into blood and 90% cell release for 1000 MCF-7 cells/mL with 90% viability. 
 The role of the antibody as a capture moiety may be assumed by DNA aptamers. These 
aptamers were conjugated to the elements of a silicon nanowire array (SiNWA) to isolate CD4+ 
T lymphocytes (95). In addition to showing increased specificity as a result of both the aptamers 
and the nanostructured surface, the application of exonuclease I allowed for the release of 97% of 
captured cells with 90% viability. A similar method of rare cell capture and release via DNA 
aptamers of cancer cells was put forth as an update to the NanoVelcro Chip (96). This device was 
validated using the non-small-cell lung cancer (NSCLC) cell line A549, and release was conducted 
with the enzyme Benzonase Nuclease.  Increased purity was achieved through a second 
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capture/release pass through the device, resulting in greater than 95% purity.  The clinical utility 
of this method was demonstrated through genetic analysis of the released cells, using PCR and 
Sanger sequencing to reveal a mutation characteristic of A549 cells, KRASG12S.   
 Nanofabrication can also be conducted with titanium oxide, which can be electrospun into 
nanofibers of 100 to 300 nm diameter (97). Horizontally oriented as opposed to the vertical 
orientation of the nanoposts and nanowires described above, titanium nanofibers (TiNFs) provide 
a scaffold for CTC capture. Zhang et al. fabricated TiNFs from a spun composite of titanium n-
butoxide (TBT) and polyvinyl pyrrolidone (PVP). Through 3-mercaptopropyl trimethoxysliane 
(MPTMS) and N-maleimidobutyryloxy succinimide ester (GMBS), streptavidin was joined to the 
fiber, with biotin/avidin chemistry being exploited to join a biotinylated anti-EpCAM to the 
surface to enable cell capture.  Performance was verified using samples from gastric and colorectal 
cancer patients. SEM imaging displayed cell spreading and the interaction of cellular structures 
with the nanostructures on the substrate surface. 
 Electrospinning was used to coat a laser microdissection slide with poly(lactic-co-glycolic 
acid) (PLGA) nanofibers, yielding a transparent capture surface with the advantages of a 
nanostructured surface (98). For melanoma-specific capture, biotinylated anti-CD146 is presented 
by streptavidin linked to the PLGA nanofibers by NHS chemistry. The device was characterized 
using the melanoma cell line M229, with an 87% capture efficiency when cell suspensions were 
flowed at 1 mL/hr, with a slightly higher capture ratio when operated at 0.5 mL/hr. Two patient 
samples demonstrated the clinical application of this device as well as potential for downstream 
analysis. Following four biomarker immunocytochemical analysis which detected 43 and 36 
CTCs, individual cells could be extracted by laser microdissection for subsequent whole genome 
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analysis and Sanger sequencing. This allowed for the detection of the BRAFV600E mutation, which 
is highly relevant in the use of therapeutic BRAF inhibitors.  
 Through various chemical fabrication methods and coupling chemistries, a wide array of 
substrate surface structures has become available for use in CTC research. Nanopillar, wire, and 
fiber geometries exploit both size scale and high surface area to increase the interface between 
capture substrates and cellular structures, improving upon capture with specific antibodies alone. 
1.3.3.3 Nanoroughened Structures 
The adhesion preference of CTCs differs from that of blood cells, making nanoroughened 
surfaces an alternative technique for CTC capture (99). Nanoroughened surfaces increase the 
surface area available for adhesion, binding, and reactions. Through deposition, molding, and 
etching, nanoroughened surfaces have been fabricated to facilitate capture and post-processing of 
rare cells, including CTCs. 
The ability of RNA to reveal the tissue of origin or mutations associated with cancer 
progression makes it an important resource in CTC investigation. As such, its isolation and 
analysis is an area of interest that can be aided by the use of nanoroughened surfaces. Following 
the extraction of RNA from magnetic bead-captured CTCs, Ivanov et al. were able to recognize 
the cells as originating from the prostate by using electrodes covered in peptide nucleic acid probes 
for prostate specific antigen (PSA) RNA (100). The cells were further characterized by including 
probes for TMPRSS/ERG Type III, a gene fusion commonly found in prostate cancer. To increase 
the presentation of probes on the surface of the electrodes, a nanostructured surface of palladium 
was deposited by electroplating. The increase in binding of RNA due to the increased accessibility 
allowed for a lower detection limit, which is especially desirable given the small population size 
of CTCs. RNA binding was sensed by the electrodes when the local increase in negative charge 
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created an electrochemical signal through interaction with an electrocatalytic solution of 
Ru(NH3)6
3+ and Fe(CN)6
3-. The efficacy of this technology was shown using prostate cancer 
patient samples in an attempt to correlate CTC levels with Gleason score. 
The established interactions between cell surface features and nanoscale structures suggest 
the possibility of capture without the use of a specific capture moiety. Chen et al. exploited the 
selective adhesion of cancer cells to nanotextured surfaces when compared with blood cells by 
reactive ion etching a glass surface for use in CTC capture (99). Increased roughness correlated 
with increased capture, while the conjugation of anti-EpCAM to the nanoroughened surface was 
not shown to make a significant difference in capture for increasingly roughened surfaces. The use 
of selection by EpCAM expression causes a significant loss of information within CTCs due to 
the inherent selection of a specific EpCAM-expressing population of cells that may not give a 
complete picture of the cancer. By using nanoroughened surfaces, the use of capture antibodies is 
not necessary, showing the potential of nanoscale features to capture a metamorphic population of 
cells. 
When every additional cell captured represents a significant increase in the amount of 
information that can be obtained, the ability of nanoroughened surfaces to increase capture yield 
through increased surface area for aptamer and antibody binding and display or through direct 
capture of the cells via extracellular structure interaction shows their promise in the expanding 
field of CTC research. 
1.3.4 Graphene Oxide Chip 
Graphene oxide is a promising material as a component in applications such as delivery of 
water-insoluble cancer drugs (101), biosensors for bacterium assays and DNA detection (102, 
103), energy-storage materials (104, 105), paper-like materials (106, 107), and polymer 
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composites (108, 109). It is a derivative of graphene with oxygen functional groups on its basal 
planes and edges. Converting graphene oxide to graphene is one method used to manufacture 
graphene (108, 110). Ruoff’s group demonstrated a solution-based approach to obtain individual 
graphene oxide sheets involving chemical oxidation of graphite to hydrophilic graphite oxide, 
followed by exfoliation through ultrasonication in water (111). Graphene oxide has certain 
advantages for biological applications. It is easy to functionalize graphene oxide through 
polyethylene glycol (PEG)-based chemistry (112). Additionally, graphene oxide particle size can 
be controlled by sonication time and filtration (113). Furthermore, the optical transparency of 
graphene oxide is one of its promising characteristics for biological and medical research, allowing 
for improved imaging (114). 
Yoon et al. demonstrated the graphene oxide chip for sensitive capture of CTCs (115). 
Graphene oxide nanosheets functionalized with polyethylene glycol (PEG) were able to self-
assemble on a gold-patterned silicon surface through use of a positively charged intercalating agent 
(116, 117). A series of linker chemistries including crosslinker and biotin-avidin chemistry were 
then used to ultimately functionalize the substrate with an anti-EpCAM antibody. To characterize 
the graphene oxide chip, MCF-7, Hs-578T, and PC-3 cell lines were spiked into buffer or blood 
and flowed through the chip. The captured cells were cultured on the patterned gold surface with 
graphene oxide sheets, making use of the advantageous virtually two-dimensional capture surface. 
Blood samples from patients with breast, pancreatic, and early lung cancer were processed on the 
graphene oxide devices and 2-23 CTCs/mL were captured. Additionally, RNA was purified from 
breast cancer patient samples and analyzed for relative HER2 expression levels using RT-qPCR. 
Due to the high sensitivity of this device coupled with its potential for downstream analysis, this 
device is ideal for the study of CTCs in genitourinary cancers. 
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1.4 Applications of CTC isolation technologies 
While many technologies have been put forth to address the challenge of CTC isolation, 
their utility will only be fully realized as those technologies are incorporated into medical research 
and practice, such as use in early detection, serial monitoring of response to treatment and disease 
progression, and biological study. The collaboration between the technology developers and 
clinicians is both the foundation of this field and the path to its future. To ensure the clinical utility 
of subsequent technologies, most new CTC technologies include at the very minimum enumeration 
analysis of clinical samples from various cancers. 
Enumeration of CTCs can serve multiple purposes, including attempts to correlate with 
progression and surrogate endpoints as in the studies using CellSearch. Another potential 
application of CTC enumeration is in early disease detection. The GEDI platform has been used 
to sample for CTCs in three cohorts with the aim of assessing the potential for early detection, 
including patients with precancerous cystic lesions, patients with pancreatic ductal 
adenocarcinoma (PDAC), and a control group (118). Using a cut-off of three CTCs/mL, there was 
no detection in the control, while at least this level of CTCs was detected in 33% of patients with 
cystic lesions and 73% of patients with PDAC. Based on the disease trajectory of these patients 
with precancerous lesions, future studies could show the utility of this device for use in a cancer 
that desperately needs new techniques for early detection. 
The relative ease of serial blood sampling compared with multiple invasive biopsies points 
to the potential value of CTC isolation technologies to serially monitor patient progression and 
response to treatment. The HTMSU has been used to try to correlate CTC burden with disease 
burden using a patient-derived xenograft (PDX) mouse model of PDAC (119). CTCs were 
enumerated pre-and post-treatment, and while there was not a statistically significant correlation 
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between CTC number and tumor volume, there was a correlation between the change in CTC 
counts and the change in tumor burden. Additionally, those mice undergoing treatment with 
BKM120, a phosphatidylinositol-3-kinase inhibitor, showed a decrease in CTC burden. In 
humans, the GEM chip was not only verified with pancreatic patient samples but was also used to 
serially monitor CTC burden over the course of multiple treatment cycles in three patients, 
showing correlation tumor size as measured by CT scans (75). Response to gefitinib treatment in 
one lung cancer patient was monitored using the NanoVelcro technology, both by assessing the 
CTC burden and radiographically assessing the tumor size, as well as by conducting whole genome 
amplification and Sanger sequencing to detect relevant mutations in EGFR (120). 
As shown in the last example, enumerating CTCs may only be the tip of the informational 
iceberg, with genomic, expression, and proteomic analysis likely being able to provide insights 
into the fundamental mechanisms of how cancer spreads. The Hb Chip functionalized with an 
antibody cocktail including anti-EpCAM, anti-EGFR, and anti-HER2 has been used to study RNA 
levels of transcripts associated with various points on the spectrum of EMT in breast cancer patient 
CTCs (74). RNA in situ hybridization (ISH) was used to visualize epithelial transcripts (keratins 
5, 7, 8, 18, 19 as well as EpCAM and cadherin 1) and mesenchymal transcripts (fibronectin, 
cadherin 2, serpin peptidase inhibitor clade E). The varying levels were tracked in patients as they 
underwent treatment and increased mesenchymal marker expression was associated with clusters 
of CTCs. Additionally, RNA was sequenced yielding the discovery of enriched transcripts for 
ECM proteins, therapy resistance signatures, and transforming growth factor β (TGFβ) found in 
mesenchymal and clustering CTCs. CTCs isolated from a mouse model of pancreatic cancer using 
the CTC-iChip have undergone single cell RNA sequencing, also showing high expression of 
ECM proteins such as SPARC (121). 
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However, a major limitation to the study of CTCs is their rarity, and even 100% efficient 
separation would still yield few cells. Consequently, an area of emerging investigation is to culture 
these cells ex vivo. A technique to culture isolated cells on-chip has been optimizing using a 
modified CTC Chip, a mixture of collagen and Matrigel, and fibroblasts for coculture (122).  
Successful expansion was achieved in 14 out of 19 lung cancer patients assessed for this purpose. 
Cultured CTCs were released with trypsin for further analysis such as transwell invasion assays 
and next-generation sequencing. CTCs isolated using the CTC-iChip have also been cultured as 
spheres under hypoxic conditions in a serum-free media containing growth factors, although this 
technique only showed success in 6/36 attempts (123). These cells could then be stained using 
immunofluorescence and IHC and could undergo next-generation sequencing, revealing several 
relevant mutations. Additionally, these mutations were used to develop a drug testing regime to 
target these treatments. The use of cultured CTCs for functional testing and therapeutic guidance 
represents the crossing into the next frontier of CTC research, where the results of CTC analysis 
can be used to characterize an individual’s disease to optimize treatment. 
Continuing this thrust of using CTC isolation technologies beyond initial development into 
the study of CTCs in clinically relevant information, in this thesis, I seek to apply a nanomaterial-
based microfluidic device, the GO Chip, to the thorough investigation of CTCs in genitourinary 
cancers to address current challenges facing those diseases. 
1.5 Prostate cancer 
Prostate cancer is the second leading cause of cancer death in men in the United States 
(124). It is the most commonly diagnosed cancer in men other than skin cancer, with 1 in 8 men 
receiving this diagnosis in his lifetime. The majority of men with prostate cancer are diagnosed 
based on an elevated levels of prostate specific antigen (PSA) in the serum (125). PSA is a secreted 
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enzyme that is generally contained within the prostate, but enters the serum when there is damage 
to prostatic tissue, allowing for a simple blood test. However, there have been calls to decrease the 
frequency of PSA testing due to the possibility of overdiagnosis, i.e., the diagnosis of clinically 
indolent prostate cancer that is unlikely to lead to metastasis and/or death (126). Thus, there 
remains a need for a more informative test for prostate cancer, with an emphasis on the cancer’s 
ability to metastasize, such that severe treatments and invasive surgeries are only undergone by 
those whose cancers that truly warrant them.  
Once the disease progresses to an advanced state, a common treatment for prostate cancer 
is androgen deprivation therapy (ADT) to decrease proliferation and promote apoptosis in cancer 
cells, decreasing tumor burden and serum PSA levels (127).  However, there is often recurrence 
due to incomplete androgen ablation, which is potentially coupled with the selection of cells with 
upregulated androgen receptors or mutations allowing the recognition of anti-androgens by the 
androgen receptor. Other mutations notable in prostate cancer include PTEN deletions and the 
TMPRSS2:ERG fusion (128), while the prostate specific membrane antigen (PSMA) represents 
an additional tissue specific marker (129). Another feature of prostate cancer is the specificity with 
which it metastasizes to the bone, although the mechanisms of this specificity are not fully 
understood. This highlights a lack of physiologically relevant models for prostate cancer, as 
xenograft mice rarely undergo bone metastasis (128). CTCs therefore have the potential to provide 
a window into both the trajectory of a patient’s disease as well as unanswered questions into the 
biology of the disease. 
1.6 Bladder cancer  
Bladder cancer is the fourth most prevalent cancer in men, and affects men four times as 
frequently as it does women (130). It is historically important and the subject of much molecular 
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characterization due to the discovery of the human ras genes in the T24 bladder cancer cell line 
(131). Instances of the disease may be stratified into two tracts: non-muscle-invasive and muscle-
invasive. The intense surveillance in the form of cystoscopies and repeated surgeries to resect the 
tumors make this disease highly detrimental to both the comfort and quality of life experienced by 
the victim as well as extremely expensive to the healthcare system (132, 133). A particularly 
perilous example of invasive disease is carcinoma in situ (CIS), which can proceed to invasive 
disease. While chemotherapy and radiation are used to treat invasive bladder cancer, they do not 
completely eradicate it (132), and 50% of patients with metastatic bladder cancer die within 5 years 
(133). Drug resistance is also a common problem with invasive disease (134). For those patients 
with advanced disease, overall survival has remained unchanged for over 30 years (135), indicating 
a need for both better prognostic and diagnostic indicators in addition to more therapeutic targets. 
There are multiple methods used to diagnose bladder cancer. Endoscopy and transurethral 
biopsy are invasive procedures that pose obvious discomfort and have been known to miss CIS 
(131). Additionally, these techniques contribute to the financial burden of bladder cancer, which 
is projected to be responsible for greater than 3% of cancer-related spending by 2020 (136). A 
noninvasive exam involves the use of urine cytology, which has the drawback of low sensitivity. 
Many molecular markers have been identified with the goal of using them to make more informed 
treatment decisions, better predictions regarding the outcome of the disease, and better understand 
the underlying biology in hopes of discovering additional therapeutic targets. Biomarker 
expression in bladder cancer has a spatial component. The urothelium is organized into three 
layers, each with a corresponding cell type: basal, intermediate, and umbrella (133). An example 
of localized expression is that of EGFR. In normal urothelium, it is expressed by basal cells, 
protected from interacting with EGF in the urine by the other two layers (135). If this barrier is 
 31 
 
disturbed, EGFR may bind EGF, potentially leading to tumorigenesis. Expression may also be 
variable between primary tumors and their metastases, such as the over-expression of HER2 in 
45% of the metastases from HER2 negative primary tumors. Different stages of bladder cancer 
may also have varied expression levels. An example is the androgen receptor, which is expressed 
in bladder cancers in lower levels than in normal urothelium but at higher levels in invasive and 
high grade tumors relative to noninvasive and low grade tumors (137). The two tracts of urothelial 
cancer may involve varied molecular mechanisms, with misregulation of RB and other tumor 
suppressors being of great importance in invasive bladder cancer while issues in the MAPK 
pathway may be behind papillary disease (132). Biomarkers have applications in clinical decision 
making, surrogate endpoints, and prognostication, and easy access to tumor related specimens may 
improve their use and provide opportunities to discover new ones. 
Major challenges currently facing bladder cancer include the need for therapies for 
metastatic disease and better techniques to monitor the disease. CTCs represent a more easily 
acquired sample of biological tissue that could be used to both monitor the disease as well as serve 
as a substrate for study potential therapeutic targets. 
1.7 Mission statement and hypothesis 
CTCs have the potential to address unmet needs in the study of genitourinary cancers. As 
the population of cells preselected for their ability to enter the bloodstream, they present a clinically 
relevant population of cells that is simultaneously highly accessible as a liquid biopsy. In the ten 
years since the publication of the CTC Chip, many CTC isolation technologies have emerged, but 
it is in their application to the study of patient cohorts where they will prove their worth. 
In this thesis, I have applied the highly sensitive GO Chip technology to the study of CTCs 
in prostate and bladder cancers and have taken steps to improve the technology to further its 
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clinical utility. Following characterization of prostate CTCs by both immunofluorescence staining 
and RNA expression analysis, I looked to clinical outcomes to determine which parameters can 
best inform us about a patient’s disease. I then examined specific molecular markers first in 
prostate cancer, then in bladder cancer, to further investigate the metastatic process. Finally, I 
explored different techniques to release cells captured on chip to enable further molecular 
characterization. Through this work, I furthered our lab mission of taking advantage of current 
technology and applying it to pressing clinical problems. 
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2.1 Abstract 
Rates of progression and treatment response in advanced prostate cancer are highly 
variable, and there is a clear need for non-invasive methods to assess the molecular characteristics 
of these tumors in real time. The unique potential of circulating tumor cells (CTCs) to serve as a 
clinically useful liquid biomarker is due to their ability to inform via both enumeration and RNA 
expression. We used a microfluidic graphene oxide based device (GO Chip) to isolate CTCs from 
the whole blood of 41 men with metastatic castration-resistant prostate cancer. CTCs were detected 
in all 41 samples (median: 20 CTCs/mL, range: 3-166 CTCs/mL). We observed CTCs present in 
clusters in 26/41 patients (63.4%). The cluster size ranged from 2-8 CTCs/cluster, and the 
percentage of CTCs present in samples as clusters ranged from 0-54.8%. Additionally, we 
determined the expression of 96 genes of interest by RT-qPCR. We then conducted multivariate 
analyses to determine the genes most closely associated with overall survival, PSA progression, 
and radioclinical progression. Scoring of genes based on relative expression of CD44, CDH1, 
EPCAM, ERCC1, PIK3CA, STAT3, TGFB1, and ZEB2 produced a score that accurately 
predicted overall survival (AUC = 0.88). This signature, comprised of high expression of stemness 
genes and low expression of epithelial and mesenchymal genes, implicates an undifferentiated 
CTC phenotype as a marker of poor prognosis in this setting. 
Chapter 2 Isolation and transcriptome analysis of CTCs in prostate cancer 
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2.2 Introduction 
While men with metastatic castration resistant prostate cancer (mCRPC) have a median 
survival of approximately 18 months, there is substantial heterogeneity and time-to-progression 
varies widely (138-140). Additionally, given the evolving treatment landscape, there is a clear 
need for better biomarkers of progression and treatment response in order to help guide therapeutic 
decisions. While soft tissue and bone biopsies can provide the necessary molecular information, 
many men with mCRPC have already undergone multiple prior invasive biopsies, and the tissue-
based information is representative of only that single disease site.  
A liquid-biopsy based approach offers the potential for repeated, non-invasive 
measurements and may more widely sample the overall disease state. This could potentially be 
furnished by circulating tumor cells (CTCs), which are shed from tumors and can be detected in 
the blood stream (141). In addition to giving insight into the burden of disease, these cells can 
provide further insight into the overall molecular state and risk of progression through the analysis 
of gene expression and the phenotypes of the traveling cells (142). However, key obstacles to 
capturing CTCs include their rarity and the millions of surrounding white blood cells and red blood 
cells (143). To best interrogate CTCs, they must be detected with high yield and sufficient purity. 
This problem has been addressed with a host of isolation technologies (17). Notably, the 
first FDA approved CTC isolation technology, CellSearch, has been used to establish survival 
differences based on CTC enumeration (24, 33, 34). This macroscale technology uses a magnetic 
ferrofluid conjugated with an antibody against the epithelial cellular adhesion molecule (EpCAM) 
to capture EpCAM-expressing cells from 7.5 mL whole blood (32). For increased sensitivity and 
flexibility of downstream analysis, microfluidics and nanomaterials (16) have been developed to 
isolate and study CTCs (77, 144-146). While there exist many CTC isolation technologies that 
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separate CTCs based on their size relative to white blood cells, the observation in other cancers 
that CTCs are larger than white blood cells has not held in prostate cancer (44, 147, 148), leading 
to an emphasis on the use of immunocapture. 
The nanomaterial-based graphene oxide chip (GO Chip) affords highly sensitive capture 
of rare cells with low white blood cell contamination (115). Optimized with cell line spike-in 
samples with as few as 3-5 cancer cells per milliliter of whole blood, the device showed promise 
in the capture of PC-3 cells under physiologically relevant conditions and concentrations (115). 
Coupled with the capability for downstream molecular and morphologic analysis, the GO Chip is 
poised to enable CTC enumeration, characterization, and RNA expression from the whole blood 
of patient samples (115). Its efficiency and sensitivity allow for evaluable results from only 1 mL 
of blood processed on a single chip. Toward the goal of using CTCs to provide clinically relevant 
molecular information that could eventually be utilized to assist with patient management, we 
undertook a prospective study of 41 men with mCRPC. We sought to utilize captured CTCs and 
extracted RNA from parallel GO Chips to determine CTC characteristics associated with 
progression and survival in advanced prostate cancer. 
2.3 Methods 
2.3.1 Patient sample acquisition 
Blood samples were collected with informed consent from 41 patients with mCRPC 
recruited under institutional approved IRB (HUM00052405) between August 2013 and November 
2016 using EDTA tubes. Processing occurred on the day of blood draw. Four healthy male controls 
were recruited internally and processed in the same manner as patient samples. 
In addition to overall survival, PSA at the time of blood draw, radiographic, and clinical 
progression events were recorded. PSA progression was defined using the PCWG3 criteria of an 
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increase of greater than or equal to 25% from the nadir, with a minimum increase of 2 ng/mL 
(149). Radioclinical progression was also used as a clinical endpoint using the date of whichever 
happened earliest. Radiographic progression entailed one of three events: 20% or more increase in 
the sum of the diameters of soft-tissue target lesions based on RECIST criteria applied to CT scans; 
an increase of at least 5 mm in the short axis of a previously normal lymph node (this lymph node 
must be at least 1.0 cm in the short axis); or at least two new bone lesions. Clinical progression 
was defined as worsening disease-related symptoms or new cancer-related complications. 
2.3.2 Cell culture 
The prostate cancer cell line PC-3 cell line was used to generate a scanning electron 
microscopy image to demonstrate cell capture on the GO Chip. This cell line was a generous gift 
from the lab of Mark L. Day following their purchase from ATCC. They were maintained in RPMI 
1640 (Gibco) supplemented with 10% fetal bovine serum (FBS, Corning) and 1% antibiotic-
antimycotic (Gibco). Cells were maintained in a 37°C incubator with 5% CO2. The cell line tested 
negative for Mycoplasma contamination as assayed using the Lonza Mycoalert on February 27, 
2017. 
2.3.3 Device fabrication 
Fabrication of the graphene oxide chip (GO Chip) has been described previously (115). 
Briefly, a suspension was made by probe tip sonicating graphene oxide (CheapTubes.com) and 
tetrabutyl ammonium hydroxide (TBA, Fluka) in dimethylformamide (Sigma-Aldrich). A 
phospholipid-polyethyleneglycol-amine (PEG, NOF America Corporation) was added to the 
resulting suspension and bath sonicated for 1 hour. Silicon wafers with gold features fabricated 
using photolithography were dipped in the suspension to allow self-assembly of the GO-TBA-
PEG onto the gold. This pattern was then enclosed in a polydimethylsiloxane (PDMS, Dow 
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Corning) microfluidic chamber. The crosslinker N-γ-maleimidobutyryl-oxysuccinimide ester 
(GMBS, Pierce) was then added to the devices and incubated at which point tubing (Tygon) was 
inserted. Following a wash, NeutrAvidin (Invitrogen) was added to the devices via syringe pump 
(Harvard Apparatus). The devices could be stored at 4º C until use, at which time biotinylated anti-
EpCAM (Table 2-1) in 1% bovine serum albumin (BSA, Sigma) was added prior to sample 
processing. 
Table 2-1 Antibody information. 
Antibody Conjugate Application Company Catalog 
number 
Clone 
Goat anti-human 
EpCAM 
Biotin Cell capture R&D Systems BAF960 Polyclonal 
Mouse IgG2a anti-
human cytokeratin 
7/8 
N/A Primary 
antibody 
BD Biosciences 349205 CAM5.2 
Mouse IgG1 anti-
human CD45 
N/A Primary 
antibody 
BD Biosciences 555480 HI30 
Goat anti-mouse 
IgG2a 
Alexa 
Fluor 546 
Secondary 
antibody 
ThermoFisher A-21133 Polyclonal 
Goat anti-mouse 
IgG1 
Alexa 
Fluor 488 
Secondary 
antibody 
ThermoFisher A-21121 Polyclonal 
2.3.4 Scanning electron microscopy 
To fix cells on the device for scanning electron microscopy (SEM) imaging, the PDMS 
layer was removed and the substrate was fixed in 2.5% glutaraldehyde (Electron Microscopy 
Sciences) for one hour. The substrate was then washed twice with PBS and dehydrated through 
successive 10 minute dips in increasing concentrations of ethanol (50%, 70%, 95%, 100% twice). 
The substrate was dipped twice in hexamethyldisilazane (HDMS, Electron Microscopy Sciences) 
for 10 minutes each and then dried overnight in a chemical hood. The fixed substrate was then 
sputter coated with carbon and imaged on a FEI Nova 200 Nanolab. 
2.3.5 Patient sample processing 
Following blocking with BSA, 1 mL whole blood was introduced into the GO Chip at a 
flow rate of 1 mL/hr. Devices were then flushed with a total volume of 6 mL phosphate buffered 
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saline (PBS, Gibco) at 100 μl/min immediately following blood flow. Subsequent steps were 
determined based on the ultimate application of the device in the work-flow. For devices that 
would be stained for enumeration, the contents of the PDMS chamber were fixed using 4% 
paraformaldehyde (PFA, ThermoFisher). These devices were then stored at 4°C until they were 
stained. On a parallel device, RNA extraction was performed by first flowing RNA extraction 
buffer (a component of the PicoPure® RNA Isolation Kit, Arcturus). The device and syringe were 
then incubated for 30 minutes at 42°C, after which DEPC water (ThermoFisher) was flowed. 
Collected RNA extraction buffer and DEPC water from the device outlet were stored at -80°C 
until purification.  
2.3.6 Immunofluorescence staining 
Subsequent to processing and fixation of the sample, immunofluorescence staining was 
performed on-chip using a syringe pump. Cells were permeabilized using Triton X (Sigma) and 
then blocked a combination of goat serum (ThermoFisher) and BSA. See Table 2-1 for all antibody 
information. Primary antibodies against CD45 and cytokeratin 7/8 were detected using the 
appropriate secondary antibodies labeled with Alexa Fluors 488 and 546. Antibodies were 
suspended in 1% BSA while 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI, Invitrogen) 
in PBS was used to label cell nuclei. Imaging of fluorescence staining was conducted on a Nikon 
Eclipse Ti fluorescence microscope using either a 10x or 20x objective. Images were captured 
using a QImaging cooled mono 12-bit camera and analyzed using NIS-Elements software. Those 
nucleated cells expressing CK but not CD45 (DAPI+/CK+/CD45- cells), were counted as CTCs. 
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2.3.7 Quantitative reverse-transcription polymerase chain reaction (RT-qPCR) 
Bulk cell lysates extracted during sample processing from 36 patients and four healthy 
controls were subsequently purified using the remaining components of the PicoPure® RNA 
Isolation Kit; five patients were processed only for enumeration and not RNA expression analysis 
(Table 2-2). Purification was conducted according to the manufacturer’s protocol. Purified RNA 
was reverse transcribed to cDNA according to the manufacturer’s protocol using an Ambion kit 
(ThermoFisher). The cDNA was pre-amplified after which it underwent RT-qPCR using an 
Applied BiosystemsTM TaqMan® Gene Expression Assay. Using the BioMark HD qPCR platform 
(Fluidigm), CT levels were determined for 96 genes of interest (complete list, Table 2-3) in the 
following categories: apoptosis, blood cell, cell cycle, cell junction, cytoskeleton, developmental, 
DNA repair, extracellular matrix, epithelial, growth factor, hormone, housekeeping, 
inflammation/immune system, long noncoding RNA, mesenchymal, oncogene, proliferation, 
stemness, transcription factor, and tumor suppressor. 
  
Table 2-2 Sample flow through study. 
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Table 2-3 List of 96 genes analyzed by RT-qPCR. 
Gene Category 
BCL-xL Apoptosis 
CASP3 Apoptosis 
XIAP Apoptosis 
CD3D Blood cell 
CD11B Blood cell 
CD20 Blood cell 
CD45 Blood cell 
CD33 Blood cell 
CD34 Blood cell 
PTPRN2 Cell cycle 
CCND1 Cell cycle 
CHP1 Cell cycle 
KLF4 Cell cycle 
PSME3 Cell cycle 
DSP Cell junction 
EVPL Cell junction 
JUP Cell junction 
CTNNA1 Cytoskeleton 
CTNNB1 Cytoskeleton 
CTNND1 Cytoskeleton 
PKP2 Cytoskeleton 
FOXC1 Transcription factor 
FOXC2 Transcription factor 
ERCC1 DNA repair 
COL1A2 ECM 
COL3A1 ECM 
LGALS3BP ECM 
MMP2 ECM 
MMP9 ECM 
SPARC ECM 
TIMP1 ECM 
TIMP2 ECM 
CDH1 Epithelial 
EPCAM Epithelial 
KRT7 Epithelial 
KRT8 Epithelial 
KRT14 Epithelial 
KLK3 Epithelial 
EMP2 Epithelial 
MUC1 Epithelial 
TROP2 Epithelial 
FGF18 Growth factor 
IGFBP5 Growth factor 
TGFB1 Growth factor 
AR Hormone 
GAPDH Housekeeping 
ACTB Housekeeping 
UBB Housekeeping 
CXCL16 Inflammation/Immune system 
CXCR1 Inflammation/Immune system 
IL6 Inflammation/Immune system 
IL8 Inflammation/Immune system 
MTOR Inflammation/Immune system 
NFKB1 Inflammation/Immune system 
PD-1 Inflammation/Immune system 
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PDL-1 Inflammation/Immune system 
XBP1 Inflammation/Immune system 
XIST lncRNA 
HOTAIR lncRNA 
CDH2 Mesenchymal 
CDH11 Mesenchymal 
VIMENTIN Mesenchymal 
KRT5 Mesenchymal 
SNAI1 Mesenchymal 
SNAI2 Mesenchymal 
ZEB1 Mesenchymal 
ZEB2 Mesenchymal 
CD146 Mesenchymal/endothelial 
ERBB2 Oncogene 
ERG Oncogene 
FOLH1 Oncogene 
ALK Oncogene 
EGFR Oncogene 
KRAS Oncogene 
MAPK1 Oncogene 
NTRK2 Oncogene 
PIK3CA Oncogene 
MKI67 Proliferation 
MLPH Signal transduction 
SERPINB6 Signal transduction 
STAT3 Signal transduction 
ALDH1A1 Stemness 
ALDH1A3 Stemness 
CD24 Stemness 
CD44 Stemness 
CD44v6 Stemness 
CD133 Stemness 
BMi1 Stemness 
ABCG2 Stemness/Drug resistance 
ETV1 Transcription factor 
TMPRSS2 Transcription factor 
ELF3 Transcription factor 
TP53  Tumor suppressor 
PTEN Tumor suppressor 
RB1 Tumor suppressor 
PTCH1 Tumor suppressor 
 
Table 2-4 Detected genes. 
Genes detected in one or more patients (CT < 30) Detected in three or more patients? 
ABCG2 Yes 
ACTB Yes 
ALDH1A1 Yes 
ALDH1A3 Yes 
AR Yes 
BCL-xL Yes 
BMi1 Yes 
CASP3 Yes 
CCND1 Yes 
CD11B Yes 
CD146 Yes 
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CD20 Yes 
CD24 Yes 
CD33 Yes 
CD3D Yes 
CD44 Yes 
CD45 Yes 
CDH1 Yes 
CDH2 Yes 
CHP1 Yes 
CTNNB1 Yes 
CTNND1 Yes 
CXCL16 Yes 
CXCR1 Yes 
EPCAM Yes 
ERBB2 Yes 
ERCC1 Yes 
FOXC1 Yes 
FOXC2 Yes 
GAPDH Yes 
IL8 Yes 
JUP Yes 
KLF4 Yes 
KRAS Yes 
LGALS3BP Yes 
MAPK1 Yes 
MKI67 Yes 
MMP9 Yes 
MTOR Yes 
NFKB1 Yes 
PIK3CA Yes 
PSME3 Yes 
PTEN Yes 
RB1 Yes 
SERPINB6 Yes 
SPARC Yes 
STAT3 Yes 
TGFB1 Yes 
TIMP1 Yes 
TIMP2 Yes 
TP53 Yes 
TROP2 Yes 
UBB Yes 
VIMENTIN Yes 
XBP1 Yes 
XIAP Yes 
ZEB1 Yes 
ZEB2 Yes 
CD44v6 No 
DSP No 
EGFR No 
ELF3 No 
EMP2 No 
ETV1 No 
EVPL No 
FOLH1 No 
IGFBP5 No 
IL6 No 
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KLK3 No 
KRT8 No 
MLPH No 
MUC1 No 
PDL-1 No 
PKP2 No 
SNAI1 No 
TMPRSS2 No 
XIST No 
 
2.3.8 Statistical analysis 
The primary outcome of interest was overall survival. Data variables were related to either 
enumeration or RNA, and in the case of enumeration included CTCs/mL, the presence of clusters, 
the number of clusters, the percentage of CTCs in clusters, the average number of CTCs/cluster, 
and the maximum number of CTCs/cluster. The base ten log of the enumeration variables was 
taken for the purposes of analysis. Analyses were performed using Excel and R (150) with the 
following R packages: rpart (151), survival (152), and survivalROC (153). The CTC enumeration 
variables were compared to the clinical metrics using Cox proportional hazards models and 
Kaplan-Meier survival analysis. The Wald test was used to determine significance for Cox 
proportional hazards modeling, while the log-rank test was used in the Kaplan-Meier analysis. In 
other comparisons, statistical significance was determined using the Mann-Whitney test. A 
nominal p-value of less than 0.05 was considered statistically significant. RT-qPCR results were 
first normalized to the mean of three housekeeping genes (GAPDH, ACTB, UBB) to obtain a ΔCt 
value, and then background corrected by deducting the mean expression level of each in the four 
healthy controls to obtain a ΔΔCt value, and subsequently analyzed as log2(2-ΔΔCt + 1). To select 
genes for the generation of a point-based score, analysis conducted with the rpart package in R 
was used as a screening mechanism, with nominally significant genes being considered. 
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2.4 Results 
2.4.1 Clinical cohort 
We assessed 41 metastatic castrate resistant prostate cancer patients over the course of this 
study (Table 2-5). The median patient age was 73 years (range: 50-84 years), while the median 
baseline PSA level was 37.9 ng/mL (range: 1.2-6433 ng/mL). The median number of prior 
treatments other than first-line hormonal therapy was one (range: 0-7), and at the time of CTC 
collection there were 17 patients receiving abiraterone, four receiving cabazitaxel, two receiving 
cabozantinib, seven receiving docetaxel, eight receiving enzalutamide, one receiving olaparib, and 
one receiving pembrolizumab. During the study and follow-up period, 34 patients experienced 
PSA progression; 37 experienced radioclinical progression as defined by a ≥20% increase in the 
sum of the soft tissue lesion diameters during computed tomography, ≥2 new bone lesions on bone 
scan, or symptomatic progression (worsening pain aggravation or new cancer-related symptoms); 
and 22 patients died. For surviving patients, the median time to last follow-up was 19.1 months 
(range: 3.3-37.8 months). Median time to death was 17.5 months (range: 2.6-39.6 months). 
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Table 2-5 Clinical cohort information. 
Number of patients 41 100% 
Age   
Median (range) 73 (50-84) 
Race   
Caucasian 39 95.1% 
Black 3 7.3% 
Castrate resistant 41 100% 
Performance status   
0 15 36.6% 
1 22 53.7% 
2 3 7.3% 
Prostate-specific antigen (ng/mL)   
Median (range) 37.9 (1.2-6433.1) 
Metastatic disease 41 100% 
Visceral metastases 11 26.8% 
Number of prior therapies   
Median (range) 1 0-7 
Therapy at time of collection   
Abiraterone 17 41.5% 
Cabazitaxel 4 9.8% 
Cabozantinib 2 4.9% 
Docetaxel 7 17.1% 
Enzalutamide 8 19.5% 
Olaparib 1 2.4% 
Pembrolizumab 1 2.4% 
 
2.4.2 Circulating tumor cell detection, enumeration, and gene expression analysis by RT-qPCR 
in clinical samples 
To investigate the presence of CTCs in clinical samples, we processed 1 mL of whole blood 
from 41 metastatic castrate resistant prostate cancer patients for CTC enumeration (Figure 2-1). 
CTCs were detected in all 41 samples with the number of CTCs ranging from 3-166 CTCs/mL 
(median: 20 CTCs/mL, Figure 2-2). The median number of CTCs detected in healthy controls was 
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5 CTCs/mL (range: 3-14 CTCs/mL). CTC counts for patients were significantly higher than those 
for healthy controls (p = 0.013). 
For 36 of the patients, we had the opportunity to run a parallel microfluidic device that 
ultimately yielded RNA following cell lysis and purification, which was used for RT-qPCR (Table 
2-2). Results from one patient sample were discarded due to insufficient expression of 
housekeeping genes suggesting lack of sufficient RNA for analysis. In the remaining 35 patient 
samples, 77 of the 96 genes were detectable (CT < 30) in at least one patient, and 58 genes were 
detectable at this threshold in at least three patients (Table 2-3, Table 2-4). 
 
  
Figure 2-1 Graphene oxide chip-enabled isolation of prostate circulating tumor cells. (A) Sample workflow. Two parallel devices 
were processed, one each for circulating tumor cell enumeration and RNA extraction. (B) Scanning electron micrograph of PC-3 
cell (red pseudocolor) and white blood cells (green pseudocolor) on-chip. Flower patter is 100 μm in height and width. 
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2.4.3 Circulating tumor cell cluster detection in patient samples 
Figure 2-2 CTC enumeration in mCRPC patients. (a) Circulating tumor cell (CTC) enumeration results for 41 metastatic castrate 
resistant prostate cancer patient samples (range: 3-166 CTCs/mL, median: 20) and four healthy controls (range: 3-14 CTCs/mL, 
median: 5). *denotes p < 0.05. (b, c) Examples of CTCs captured on-chip as well as non-specifically bound white blood cells 
(WBCs). Nuclear staining is shown in blue, cytokeratin 7/8 in red, and CD45 in green. Scale bar is 10 μm. 
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While processing patient samples, we observed groups of two or more adjacent CTCs 
(Figure 2-3a, b), termed CTC clusters. These clusters were only present in patient samples (26/41, 
63.4%) and not healthy controls. Both interpatient and intrapatient heterogeneity were evident 
from the captured clusters, as cells within the clusters showed varying size and cytokeratin 
expression. Clusters consisted of up to eight CTCs per cluster (Figure 2-3c) with the majority of 
the clusters comprising fewer numbers of cells. The percentage of CTCs captured in the form of 
clusters also varied greatly among patients from 0 to 54.8% (Figure 2-3d). 
 
2.4.4 Gene-CTC cluster association 
We next examined the relationship between gene expression and the measures of clusters 
to determine potential associations. The association between gene expression and the number of 
clusters or the percentage of CTCs detected in clusters from each patient sample was examined 
through linear modeling of these parameters as continuous variables (Figure 2-4). If the 
relationship between the enumeration variable and the gene expression had a negative linear 
Figure 2-3 CTC clusters in mCRPC patient samples. (a, b) Examples of captured circulating tumor cell (CTC) clusters. CTCs 
captured within clusters had heterogeneous size and cytokeratin expression. The capture pattern is outlined with a dashed line for 
visualization purposes; scale bar is 10 μm. (c) Captured CTC clusters ranged in size from two to eight cells per cluster. (d) The 
percentage of captured CTCs present in clusters ranged from 0 to 54.8%. 
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coefficient, that meant the gene expression decreased as the enumeration variable increased (i.e. 
as the number of clusters or percentage of CTCs in clusters increased). CTNND1 and ZEB2 were 
negatively associated with the number of clusters present per sample, and CTNND1 and FOXC1 
were negatively associated with the percentage of CTCs found in clusters (p < 0.05).  
 
2.4.5 Exploratory single variable analysis  
 To assess the clinical relevance of the experimental data obtained, we compared 
CTC metrics and gene expression with overall survival, PSA progression, and radioclinical 
progression. While none of the enumeration variables were statistically significant in the 
Figure 2-4 Linear modeling of gene expression based on cluster metrics. (A) Linear association of gene expression with number 
of CTC clusters. Two genes, CTNND1 and ZEB2, showed a significant negative association. (B) Linear association of gene 
expression with percentage of CTCs in clusters versus present as single cells. FOXC1 showed a significant positive association 
while CTNND1 showed a significant negative association. (C, D) R2 values for linear associations of gene expression with number 
of CTC clusters and percentage of CTCs in cluster versus present as single cells, respectively. Data is plotted as the linear 
coefficient or R2 ± the 95% confidence interval; */red denotes p < 0.05. 
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univariable Cox proportional hazards models, patients with a high number of clusters relative to 
the median had a shorter time to radioclinical progression than those with a low number of clusters 
in the Kaplan-Meier survival analysis (log rank p < 0.05, Figure 2-5).  
 
 To construct a bimodal point-based metric relating gene expression (Figure 2-6) to clinical 
outcomes, we used cut-points to classify patients in to high and low survival groups as determined 
by subsequent Kaplan-Meier analysis. Cut-points were generated using regression tree analysis 
from the rpart (recursive partitioning) package in the R software environment. The rpart package 
uses regression models based on the input data set to find the variable and location that best splits 
the data into two groups, where best is defined as minimizing the risk of misclassification. In this 
case, the input data consisted of the gene expression levels and clinical outcomes. Genes associated 
with overall survival included CD44, CDH1, EPCAM, ERCC1, IL8, PIK3CA, STAT3, TGFβ, 
TIMP2, and ZEB2. The genes CDH1, CD146, FOXC2, and ZEB2 were associated with PSA 
progression, while the genes associated with radioclinical progression included ACTB, CDH1, 
CDH2, CD3D, CD45, CASP3, CD146, CXCR1, KLF4, KRAS, MKI67, MMP9, RB1, SPARC, 
XBP1, and ZEB2. 
 
Figure 2-5 Relationship between radioclinical progression and number of 
clusters as determined through Kaplan-Meier analysis (p < 0.05). 
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2.4.6 Multivariate analysis derived from univariate survival and progression analysis 
Using these pre-screened genes, we developed a series of prognostic scores to predict 
survival/progression. Based on gene expression relative to the cut-point, we assigned genes a point 
value of 0 or 1 based on whether their gene expression value fell above or below the cut-point 
based on its relationship to shorter survival or progression time. For example, in the case of overall 
survival, patients expressing greater levels of CD44 than the cut-point were assigned 1 point, while 
patients expressing lower levels of CDH1 than the cut-point were assigned 1 point. Conversely, 
patients expressing lower levels of CDH1 than the cut-point were assigned 1 point, while patients 
expressing higher levels of CDH1 than the cut-point were assigned 0 points. The values for each 
of the genes were then added in different combinations with all subsets considered and used to 
generate receiver operating characteristic (ROC) curves, with the scores ranging from 0 to the 
Figure 2-6 Heatmap of log2 fold changes (FC) relative to healthy control background for 58 genes detected in patient samples. 
Associated gene categories are shown to the right of the gene list. 
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number of genes in the score. These curves were then evaluated based on the area under the curve 
(AUC), with AUCs approaching one having greater discriminatory ability. The 95% confidence 
interval (CI) was generated by resampling, with 104 bootstrap samples. Additionally, the Cox 
proportional hazard ratio (154) was calculated for each score. 
Of the significant genes established for overall survival, a set of eight genes ultimately had 
the best prognostic power: CD44, CDH1, EPCAM, ERCC1, PIK3CA, STAT3, TGFB1, and ZEB2 
(Figure 2-7a). The resulting ROC had an AUC of 0.88 (95% CI: 0.69-0.98, Figure 2-7b). 
Assessing the score using the Cox proportional hazard model yielded a hazard ratio of 1.83 (95% 
CI: 1.33-2.51) for overall survival, representing the increased risk between the patient groups one 
unit apart on the numerical score. Using the same methods to relate the subsets of significant genes 
to radioclinical progression produced a five-gene score consisting of CD3D, MMP9, RB1, XBP1, 
and ZEB2 (AUC: 0.82, 95% CI: 0.67-0.96, Figure 2-9). This score carried a hazard of 1.51 (95% 
CI: 1.19-1.92) for radioclinical progression. Finally, investigation of combinations of genes related 
to PSA progression resulted in a three-gene score: CDH1, CD146, and ZEB2 (AUC: 0.69, 95% 
CI: 0.47-0.87, Figure 2-8); and a proportional hazard of 1.75 (95% CI: 1.17-2.63). 
 
Figure 2-7 Relationship between RNA expression and overall survival. (a) Kaplan-Meier curves for genes with statistically 
significant relationships with overall survival used to construct the optimized point-based score. (b) Scores were optimized by 
maximizing the area under the curve (AUC) of the associated receiver operating curve. 
 53 
 
 
 
 
2.5 Discussion 
To best study both the underlying biology and disease trajectory of prostate cancer, there 
is a need for an informative biomarker that is both accessible and capable of capturing tumor 
heterogeneity. CTCs provide this opportunity as a readily-available liquid biopsy. The 
incorporation of microfluidics into CTC research offers substantial promise for overcoming the 
hurdles of low CTC counts and the immense quantity of surrounding normal blood cells. It was 
Figure 2-9 Relationship between RNA expression and radioclinical progression. (A) Kaplan-Meier curves for all genes with 
statistically significant relationships with radiographic or clinical progression used to construct the optimized point-based score. 
(B) Scores were optimized by maximizing the area under the curve (AUC) of the associated receiver operating curve. 
Figure 2-8 Relationship between RNA expression and PSA progression. (A) Kaplan-Meier curves for genes with statistically 
significant relationships with overall survival used to construct the optimized point-based score. (B) Scores were optimized by 
maximizing the area under the curve (AUC) of the associated receiver operating curve.  
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our goal to integrate an ultra-sensitive CTC isolation technology enabling both 
immunofluorescence characterization and RNA expression analysis in order to investigate the 
relationship of the CTC-based results with key oncologic outcomes. We detected CTCs from 
whole blood samples from 41 mCRPC patients, and were additionally able to observe clusters in 
over 60% of samples. Following qRT-PCR analysis, we compared RNA expression with survival 
and progression, and in the process, determined a set of eight genes that comprised a score 
prognostic of overall survival. Our work here is an example of a strategy to incorporate CTC-
related metrics with clinical data.   
Prior studies have also used cell enrichment technologies coupled with RT-qPCR to study 
prostate CTCs. For example, mCRPC patients with AR-V7-positive CTCs displayed abiraterone 
and enzalutamide resistance, indicating the potential for liquid biopsy approaches to provide 
predictive information (155). The original microfluidic CTC-Chip was used to study prostate 
CTCs in localized and metastatic patients, with CTCs detected in 23/36 metastatic patients (144). 
RT-qPCR was also used for further analyses, in this instance, to detect the TMPRSS2-ERG fusion 
in 9/20 metastatic patients. The next-generation CTC chips such as the Herringbone (HB) Chip 
(145) and the geometrically enhanced differential immunocapture (GEDI) chip (69) have also been 
applied to prostate cancer. The HB Chip was used to investigate androgen receptor (AR) signaling 
through immunofluorescence staining for PSA and PSMA (156), while further 
immunofluorescence characterization by the GEDI chip examined ERG expression (70). Recently 
the CTC-iChip was used to reveal the role of noncanonical Wnt signaling through single-cell 
RNA-Seq of prostate CTCs from 13 patients isolated by negative selection (146). However, the 
majority of these studies reported on a limited set of genes. To our knowledge, our study is the 
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first to apply microfluidics-enabled study of CTC enumeration and RNA expression in a cohort of 
this size using a gene panel of this size. 
Another key potential advantage of the approach utilized here is the ability to observe 
clusters of CTCs, which may provide important prognostic information. CTC clusters have 
previously been observed in prostate cancer patient samples analyzed using the CellSearch 
technology, where they have at times been detected in as many as one third of patients (35, 157). 
CTC clusters have also been visualized using the Epic Sciences platform, some of which have 
been shown to be AR-V7 positive (43). Additionally, the HB Chip found CTC clusters in 6 out of 
64 patients sampled at multiple time points, and detection of CTC clusters at any time point was 
associated with decreased overall survival (29). This suggests a future direction for our technology, 
in which serial sampling may provide more prognostic information. Importantly, the fraction of 
CTC clusters reported in the present study (63.4%) suggests that the GO Chip may be less 
disruptive to cell-cell interactions and have greater sensitivity for identifying these clusters.  
The GO Chip also facilitated RNA extraction from limited numbers of cells for gene 
expression analysis and subsequent comparison with clinical parameters. We identified a number 
of genes that were associated with overall survival, PSA progression, and radioclinical 
progression, and we performed exploratory analyses to determine which set of genes were most 
strongly associated with these outcomes. In our discovery analysis, we found 10 genes where high 
or low expression could be correlated with overall survival through Kaplan-Meier analysis. Of 
these 10 genes, eight comprised a score that produced a highly predictive receiver operator curve 
with an AUC of 0.88. Three of the genes, CDH1, EPCAM, and ZEB2, are reflective of epithelial 
or mesenchymal phenotypes. That the low expression of both the epithelial and mesenchymal 
genes was associated with lower overall survival may suggest the importance of a transitory 
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phenotype in leading to disease progression. This potentially undifferentiated phenotype is also in 
concordance with the high CD44 expression associated with shorter overall survival, as CD44 is a 
cancer stemness marker in prostate cancer (158). Low ZEB2 was also implicated in the scores for 
PSA progression and radioclinical progression, while low CDH1 was implicated in the score for 
PSA progression, suggesting an emerging theme. Additionally, STAT3 is activated by AR 
signaling loss and is associated with cancer stem cells (159). These observations are in line with 
previous descriptions of stemlike tumor-propagating subpopulations in prostate cancer (160).  
In our analysis of the relationship between the number of clusters and gene expression, we 
found lower expression of ZEB2 and CTNND1 as the number of clusters increased. 
Overexpression of δ-catenin has been associated with increased proliferation (161). The lower 
expression and therefore potentially lower proliferation would be consistent with an observed 
stemlike phenotype within the clusters, which would also be consistent with the lower ZEB2 
expression. In addition to CTNND1, FOXC1 was expressed at lower levels as the percentage of 
CTCs in clusters increased. FOXC1 expression is associated with poor prognosis, androgen 
independence, and angiogenesis (162), so this result may be indicative of aggressive properties in 
CTCs present as single cells.  
Our study has important limitations. Without question, this work will continue to benefit 
from longer follow-up and validation in larger cohorts, and recruitment of additional controls will 
be important to examine background levels of cytokeratin positive cells. This false positive rate, a 
marker of the balance between assay sensitivity and background noise, will need to continue to be 
refined. Furthermore, our current study makes use of bulk RNA extraction. While we have taken 
steps to subtract “background” signal from white blood cells in the form of processed healthy 
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control samples, we plan to integrate single-cell techniques into future work to better assess 
intrapatient heterogeneity. 
In addition to establishing the presence of CTC clusters in blood samples taken from 
mCRPC patients, we examined RNA expression signatures with respect to clinical outcomes. 
Using multi-gene scoring paradigm, we have identified a number of CTC-based genes associated 
with progression and death in our training cohort. Further work to validate this approach in larger 
cohorts and to explore the implications of CTC stemness is ongoing.  
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3.1 Abstract 
Activation of the EGF receptors EGFR (ErbB1) and HER2 (ErbB2) drives the progression 
of multiple cancer types through complex mechanisms that are still not fully understood. In this 
study, we report that HER2 expression is elevated in bone metastases of prostate cancer 
independently of gene amplification. In examining the role of EGFR in tumor-initiating cells 
(TICs), we found that EGFR expression was required for primary and secondary sphere formation 
of prostate cancer cells. EGFR expression was also observed in circulating tumor cells (CTCs) 
during prostate cancer metastasis. Dual inhibition of HER2 and EGFR resulted in significant 
inhibition of tumor xenograft growth, further supporting the significance of these receptors in 
prostate cancer progression. Overall, our results indicate that EGFR promotes survival of prostate 
TICs and CTCs that metastasize to bone, whereas HER2 supports the growth of prostate cancer 
cells once they are established at metastatic sites. 
3.2 Introduction 
Significant roles for the ErbB family receptors [EGFR (HER1), HER2, HER3, and HER4] 
have been suggested in prostate tumorigenesis and progression for a number of years, but the 
molecular mechanisms by which ErbB family members support the disease progression and 
metastasis is not fully understood. Aberrant activities of HER2 and EGFR have also been 
associated with development of castration-resistant disease, possibly due to compensation for the 
loss of androgen signaling (163-166). Like prostate cancer, breast cancer is a hormone-
Chapter 3 Interrogation of the role of HER2 and EGFR in prostate cancer metastasis 
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sensitive/refractory disease, and both share common sites of metastases, such as bone. Importantly, 
adjuvant treatment with HER2 inhibitors has reduced the recurrence rate by more than 50% in 
women suffering from breast cancer (167). On the basis of our findings here that ErbB receptor 
proteins are overexpressed in metastatic prostate cancer, it may be prudent that patients suffering 
from advanced disease are screened for treatment with ErbB-specific inhibitors. 
Although the role of HER2 in prostate cancer remains controversial (168), HER2 protein 
has been reported to be overexpressed during prostate cancer progression, and HER2-dependent 
signaling may support the development of castration-resistant prostate cancer (CRPC) by 
activating androgen receptor signaling through androgen ligand–independent mechanisms (166). 
Recent evidence supporting HER2 function in prostate cancer comes from a comprehensive 
immunohistochemical (IHC) evaluation of HER2 protein in a tumor array composed of 2,525 
prostate cancer samples (169). This study revealed significant associations between HER2 staining 
and advancing stage and grade of disease and tumor recurrence with only 1 in 2,525 (0.04%) cases 
exhibiting HER2 gene amplification. It is also known that EGFR overexpression is associated with 
the development of CRPC in patients (165). However, EGFR expression is not significantly 
associated with tumor differentiation, positive margins, extra-prostatic invasion, or preoperative 
prostate-specific antigen (PSA; (165)), suggesting that EGFR expression only increases during 
disease progression and in the development of castration-resistant disease. 
The intermediate state between primary and metastatic tumors and their ultimate 
metastases are circulating tumor cells (CTC), those cells that are shed and present in the blood 
stream (2). The clinical significance of CTCs has been shown in multiple cancers, including 
prostate cancer, in which the prognostic values of CTC counts above and below the cutoff of 5 
CTCs/7.5 mL whole blood have been associated with overall survival (141). Beyond enumeration, 
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novel CTC isolation technologies have also enabled further characterization, including protein 
expression by immunofluorescence (17, 115). 
HER2 expression has been investigated in CTCs, largely in work conducted in breast 
cancer. Using the FDA approved CellSearch, HER2-positive CTCs have been sought out by 
immunofluorescence, oftentimes identifying discordant HER2 status between CTCs, primary 
tumors, and metastases. Graded as having weak, moderate, and strong HER2 expression, HER2-
positive CTCs were detected in 14/58 breast cancer patients with CTCs in the GeparQuattro 
clinical trial, some of whom had HER2-negative primary tumors; HER2-positive CTCs were also 
associated with higher tumor stage (170). Another study defined HER2 CTC positivity as having 
at least 50% of CTCs displaying HER2 expression, with 7 of the 96 metastatic breast cancer 
patients with CTCs meeting that criterion (171). The expression of HER2 as well as other 
molecular markers associated with endocrine therapy resistance have been investigated in CTCs 
using CellSearch to generate an endocrine therapy index (172). This study also observed 
discordance between CTC HER2 status and the status of primary or metastatic tissue. Other studies 
have examined both CellSearch and the RT-PCR detection based assay AdnaTest on breast cancer 
cohorts. In one such study, CTC HER2-status concordance with the primary tumor was observed 
in 59% of samples, while CTC HER2-status concordance with metastatic sites was observed in 
67% of samples (173). Another study compared the two tests, detecting HER2-positive CTCs in 
41% of metastatic breast cancer patients by CellSearch and 47% of patients by AdnaTest (174). 
That same study detected HER-positive CTCs in patients with HER2-negative primary tumors in 
32% of patients by CellSearch and 49% of patients by AdnaTest. 
HER2 expression in CTCs has also be assessed using microfluidic technologies. HER2-
positive CTCs were discovered in 84% of 19 ER+/HER2- breast cancer patients as determined 
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through immunofluorescence and FACS of cells isolated by the CTC-iChip (175). CTC cultures 
derived from patients in this study exhibited HER+ and HER2- subpopulations which were 
available for drug testing (175). Antibodies against HER2 have been using for CTC isolation in 
immunocapture. In addition to using anti-HER2 along with anti-EpCAM and anti-EGFR for 
capture, a study using the Herringbone-chip also using RNA ISH for HER2 to confirm that 
captured mesenchymal cells were of tumor origin (74). A micropost chip functionalized with 
HER2 has been used to capture CTCs from five breast cancer patients along with five gastric 
cancer patients (71). 
There has also been a great deal of interest in EGFR expression in CTCs, with much of the 
investigation taking place in lung cancer facilitated by microfluidic technologies. As early 2008, 
CTCs captured using the original CTC Chip were investigated for EGFR-activating mutations 
(detected in 11/12 non-small cell lung cancer (NSCLC) patients (68)). A PDMS CTC chip was 
used to culture CTCs captured from NSCLC patients, with some of the subsequent analysis 
focusing on EGFR (122). EGFR expression was detected both through RT-qPCR and 
immunofluorescence, showing expression at both the RNA and protein level. EGFR mutations in 
CTCs isolated from an NSCLC patient were also assessed serially and in conjunction with 
treatment in a study performed using the NanoVelcro substrate (120). Tumor cells isolated from 
both blood and lung lavage samples from NSCLC using the VerIFAST platform were measured 
for EGFR expression using immunofluorescence (76). In addition to immunoaffinity methods, 
inertial sorting has also been used to isolated CTCs from NCLC patients and then interrogated for 
EGFR-activating mutations using mass spectrometry (176). CTCs isolated through CellSearch 
have been assessed for EGFR through immunofluorescence staining in breast (177), lung (178), 
and prostate cancer as well (33). 
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In this study (4), we evaluated the expression of HER2 protein in metastatic samples 
obtained from patients with prostate cancer and investigated the functional significance of HER2 
and EGFR overexpression in the osseous growth of human prostate cancer cells in vivo. The role 
of EGFR was also examined in the tumor-initiating population of prostate cancer cells, where it 
may support their survival and promote self-renewal in the bone microenvironment. In addition, 
results from patient samples suggest that EGFR may also have a role in the survival of CTCs in 
the metastatic progression of prostate cancer. 
3.3 Methods 
3.3.1 Cell culture and inhibitors 
LNCaP, MCF7, BT-474, and SK-BR-3 were purchased from ATCC. C4-2B and C4-2B 
luciferase transduced (C4-2BLuc) cell lines were obtained as previously described (18). All cell 
lines, including luciferase and knockdown cell lines, were fingerprinted (IDEXX RADIL). Cell 
lines were cultured in DMEM (Lonza), RPMI-1640 (Mediatech), 50% DMEM/50% RPMI, or T-
Medium (Gibco), supplemented with 10% FBS (HyClone), penicillin/streptomycin/Fungizone, 
and l-Glutamine (Gibco). Cells were kept in a 37°C, 5% CO2-humidified incubator. Lapatinib and 
afatinib were purchased from LC Laboratories. Cetuximab and trastuzumab were obtained from 
the Cancer Center Pharmacy, University of Michigan (Ann Arbor, MI). 
3.3.2 Generation of lentiviral vectors and stable cell lines 
3.3.2.1 ERBB2 knockdowns  
C4-2B cells were transduced with a panel of 4 lentiviral constructs containing short-hairpin 
HER2 or shVector and incubated for 6 hours. Four shHER2 oligos (MISSIONTM SHGLY) were 
obtained from SIGMA Co and tested in MCF7, LNCaP, C4-2B, and C4-2BLuc cell lines. Western 
blot analysis was used to identify HER2 protein knockdown cells as compared to shVector 
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expressing cells. The sequence that showed the highest downregulation of HER2 protein 
expression was characterized in stable cell lines (C4-2B and MCF7) following selection in 
Puromycin. The shHER2 construct reported here contained the following target sequence: 
TGTCAGTATCCAGGCTTTGTA. Other shHER2 sequences tested include 
CAGTGCCAATATCCAGGAGTT, GCCATCAAAGTGTTGAGGGAA, and 
CAGCTCTTTGAGGACAACTAT. These oligos were utilized in prostate and breast cancer cells 
(12). 
3.3.2.2 EGFR knockdowns 
A series of oligos (MISSIONTM) was directed against EGFR: 
GCTGGATGATAGACGCAGATA, GCTGCTCTGAAATCTCCTTTA, 
GCCACAAAGCAGTGAATTTAT, CCTCCAGAGGATGTTCAATAA, 
CAGCATGTCAAGATCACAGAT. These oligos were tested in LNCaP, C4-2B and C4-2BLuc 
cells. Knockdown was validated by western and found to be lethal after two passages in culture. 
3.3.3 Animal models and treatment 
All experiments began with 8-week-old male NOD/SCID mice from Jackson Laboratories. 
Mice received (right) tibia injections of 5 × 105 C4-2B cells containing either shVector (n = 10) or 
shHER2 (n = 10). After 3 weeks, the mice were sacrificed and tibiae (right and left) were removed 
and fixed in 10% formalin. For the inhibitor experiments, each mouse (n = 30) received an 
intratibial injection of 1 × 106 C4-2BLuc cells in their right tibia. Drug treatments started the 
following day for lapatinib (n = 10) and trastuzumab + cetuximab dual treatment groups (n = 10). 
Untreated control mice (n = 10) had the same tibia xenografts. Lapatinib was given orally at 100 
mg/kg 5 times per week. The inhibitor cocktail [trastuzumab (10 mg/kg) + cetuximab (3 mg/kg)] 
was given by intraperitoneal (i.p.) injections 3 times per week. After 7.5 weeks of treatment, the 
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mice were sacrificed and tibiae collected in 10% formalin. These experiments were based on 
reports of dose escalation of lapatinib (179-181) and on combinations of inhibitors (182). All 
animal experiments were approved by the Institutional Animal Care and Use Committee. 
3.3.4 IHC and tissue microarrays 
Prostate cancer tissue microarray (TMA) slides were designated TMA 85 (primary and 
bone) and TMA 142 (primary, lymph node, and liver). TMAs were prepared as previously 
described (183, 184). Formalin-fixed, paraffin-embedded (FFPE) tissue blocks with tumor 
samples were previously identified by a pathologist and processed as instructed by the IRB. 
Prostate tissue samples were taken from the radical prostatectomy series and the University of 
Michigan SPORE Rapid Autopsy Program (185). Tumors were staged and graded using the 
Gleason system (186). All tissue sections were reviewed by 2 board-certified genitourinary 
pathologists (R. Shah, L.P. Kunja) and scored for stain intensity (0–3), percent positivity, and 
subcellular location. 
The tibiae from the mice were decalcified in Decalcifier II (Leica Biosystems) for 3 hours 
before paraffin embedding. Antigen retrieval was performed for NeoMarkers' staining by 
pretreating with citrate at pH 6 with microwaving for 10 minutes, cooled for 10 minutes, and 
washed with water for 10 minutes. There was no pretreatment for Dako staining, which was stained 
using the Dako AutoStainer. All tissue sections were cut to 4-μm thickness. Hematoxylin and eosin 
(H&E) staining was analyzed, followed by IHC for the following biomarkers in serial sections: 
anti-HER2 (NeoMarkers Ab-17 1:100), anti-HER2 (Abcam EP1045Y 1:100), anti-HER2 (Dako 
A0485 manufacturer spec.), anti-EGFR (Life Technologies 31G7 1:100), anti-CK8/18 (Epitomics 
ac-9002RUO 1:100), anti-pHist3 (Abcam ab5176 1:500), anti-RANK (R&D Systems 80707 
1:500), anti-Ki-67 (Dako MIB-1 1:200), and anti-E-cadherin (ThermoFisher HECD-1 1:200). 
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3.3.5 Tissue imaging 
All photomicrographs were taken on an Olympus BX51 with a DP72 camera system using 
the CellSense software for analysis. Three different fields of cells were counted using 600x 
magnification for a total of at least 500 cells/ analysis of positive staining (RANK and Ki-67). 
3.3.6 Cell viability assay 
Five thousand C4-2B cells were seeded per well into 96-well plates, and 24 hours later, 
lapatinib was added to reach the indicated concentrations. The Titer Blue reagent (CellTiter-Blue 
Cell Viability Assay, Promega) was used to detect cell viability at 1, 24, and 48 hours of treatment 
using a fluorescent plate reader (Molecular Devices tunable SpectraMax M5). This assay was 
conducted as per the manufacturer's instructions. 
3.3.7 Western blotting 
Protein isolation and Western blotting were carried out as previously described (187), with 
these primary antibodies: anti-HER2 (NeoMarkers Ab-17) anti-HER2 (Abcam EP1045Y), anti-
EGFR (NeoMarkers H9B4), anti-α-tubulin (Upstate DM1A), and anti-E-cadherin (ThermoFisher 
HECD-1). Mouse and rabbit HRP-conjugated secondary antibodies (Bio-Rad) were used and 
illuminated by ECL (Advansta). One Western blot assay utilized IRDye 680 goat anti-mouse and 
IRDye 800 goat anti-rabbit secondary antibodies (LI-COR). 
3.3.8 Quantitative flow cytometric analysis 
Cell surface HER2 and EGFR were quantified using the Dako QIFIKIT according to the 
manufacturers' protocol. Three different passages of C4-2B cells were grown in complete T-
medium without phenol red and detached with TrypLE Express (Gibco). A total of 1 × 105 C4-2B 
cells were analyzed in triplicate. HER2-binding sites were saturated with anti-HER2 (R&D 
Systems 191924; 10 μg/mL) and EGFR sites with anti-EGFR (LSBio 225; 10 μg/mL) as primary 
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antibodies. Alexa Fluor 488 goat anti-mouse IgG (H+L) (Invitrogen; 1:400) was utilized as the 
secondary antibody. The median fluorescence intensity (MFI) was analyzed by flow cytometry 
(Accuri BD analyzer) and the number of molecules per cell calculated by FlowJo and subsequent 
extrapolation of the samples' MFI into a standard curve on the basis of the calibration beads MFI. 
3.3.9 Cell staining and prostate tumor sphere (prostasphere) formation 
C4-2B cells were prepared as described for “QIFIKIT analysis” and profiled by FACS with 
fluorescent-labeled anti-EGFR FITC (Abcam ICR10 1:40), anti-HER2 APC (B.D. Neu24.7 
1:133), and anti-RANK PE (Abcam 9A725 1:17) antibodies. Live cell staining of 1 × 106 cells 
(per analysis) was carried out in staining buffer (RPMI no phenol red with 2% FBS) in a final 
volume of 200 μL. Cells were stained for 1 hour on ice plus 10 minutes at room temperature, 
washed with 2 mL of staining buffer, filtered through cell strainer–capped tubes (Falcon 352235), 
and then resuspended in 250 μL of staining buffer with DAPI. FACS was carried out as described 
previously (188), and cells were sorted directly into T-Medium. The MoFlo XDP instrument was 
utilized for the analysis. DAPI was added for selection of viable (vs. DAPI-negative) cells where 
DAPI-positive cells (no antibody staining) were sorted as viable controls for sphere formation. For 
positive cell staining: EGFRhigh (top 5%), EGFRlow (bottom 5%), and HER2high (top 5%), 
HER2low (bottom 5%) cells were collected and seeded in triplicate at 200 cells/200 μL (96-well 
plates) in complete MammoCult medium (STEMCELL Technologies). Primary prostaspheres 
were grown for 10 days followed by disruption with trypsin and then reseeded (200 cells/200 μL 
of MammoCult medium) to develop secondary spheres after another 10 days of growth. Spheres 
were viewed using an Olympus CKX41inverted microscope. 
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3.3.10 FISH 
An ERBB2 BAC probe, which encoded for the entire gene sequence of the ERBB2 gene 
(introns and exons), was utilized for gene copy number analysis. Labeled probe was generated by 
DNase treatment of the ERBB2 gene and Nick translation incorporated Dig-dUTP nucleotides into 
dsDNA. ERBB2 cDNA was denatured by heat treatment at 75°C to produce single-strand DNA 
probe. Fixed tissues (on slides) were denatured with formamide at 42°C prior to hybridization with 
labeled probe. Fluorescent antibody to Dig-dUTP was employed for imaging and analysis. 
3.3.11 In vivo tumor imaging with firefly luciferase bioluminescence 
Mice received intraperitoneal injections of 2-mg D-luciferin and were anesthetized. Ten 
minutes after the injection, the luciferase signatures were captured using a PerkinElmer IVIS 
Spectrum with Living Image software (v4.2). 
3.3.12 CTC isolation using graphene oxide chip 
CTCs were isolated from whole blood samples taken from consented patients with prostate 
cancer under IRB: HUM52405. Procedures for microfluidic chip fabrication and CTC isolation 
using the microfluidic graphene oxide (GO) chip have been described elsewhere (115). Briefly, 
tetrabutyl ammonium hydroxide–intercalated GO nanosheets grafted with phospholipid-
polyethyleneglycol-amine were assembled on gold-patterned silicon substrates and enclosed in a 
polydimethylsiloxane (PDMS, Dow Corning Sylgard) chamber. Components of a 
functionalization chemistry could then be introduced to the assembled device via Harvard 
Apparatus syringe pump to ultimately present an antibody against the epithelial cellular adhesion 
molecule, anti-EpCAM (R&D Systems). Whole blood was flowed through the device to enable 
CTC capture, after which the device was washed and the cells were fixed. Cells were then 
permeabilized and stained on-chip with primary antibodies against cytokeratin 7/8 (CK, BD 
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Biosciences CAM5.2), CD45 (Santa Cruz 3H1363), and EGFR (Invitrogen 31G7) with the 
appropriate secondary antibodies (Invitrogen) and the nuclear stain DAPI (Invitrogen). Devices 
were scanned using a Nikon TI inverted fluorescence microscope. Nucleated CK+/CD45− entities 
were enumerated as CTCs. 
3.3.13 Statistical analysis 
Results of in vitro experiments are presented as mean ± SD or mean ± SE. The 
Student t test was used to compare continuous variables when there were 2 groups. A paired t test 
was used for paired data comparisons. Mouse tumor xenografts experiments are presented with 
means and SEs of the mean. Pairwise comparisons were made using ANOVA within the models 
at cross-sections and the Bonferroni multiple comparisons adjustment was used for pairwise tests. 
Analyses were completed using SAS 9.3 (SAS Institute). The mean values between prostasphere 
groups were compared in ANOVA by Tukey multiple comparisons using GraphPad Prism 6.0 
(GraphPad Software, Inc.). Alpha of 0.05 determined statistical significance. 
3.4 Results 
3.4.1 Assessment of HER2 in organ-confined, localized, and metastatic prostate cancer 
It is known that EGFR is overexpressed in metastatic and CRPC (165); however, the 
evaluation of HER2 protein at this stage of prostate cancer has not been investigated. Mechanisms 
of HER2 overexpression have historically been explained in the context of gene amplification, 
whereas transcriptional and posttranscriptional mechanisms leading to increased HER2 protein 
have not been critically evaluated. We utilized two distinct HER2 antibodies: the first, a cytosolic-
specific polyclonal antibody (Dako); and the second, two monoclonal antibodies that recognize 
two cytosolic epitopes (NeoMarkers). Both antibodies were used to evaluate HER2 protein in 
FFPE sections of normal prostate, localized prostate cancer, and metastatic prostate cancer. We 
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evaluated H&E-stained serial sections (Figure 3-1a, i-ii) followed by staining with the indicated 
HER2 antibodies (Figure 3-1a, iii-vi). A direct comparison of both antibodies revealed that the 
Dako antibody does not detect HER2 protein in normal prostate, but that the NeoMarkers antibody 
detects low levels of HER2 located at the basal–lateral junctions of luminal epithelium (Figure 
3-1a, iii and v). Both HER2 antibodies detected elevated protein in prostate cancer tissue (Figure 
3-1a, iv and vi), and we found that EGFR was expressed in moderate levels in localized (primary) 
cancer (Figure 3-1a, vii and viii). 
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Figure 3-1 Assessment of HER2 in organ-confined, localized, and metastatic prostate cancer. a) Serial sections of normal prostate 
(i, iii, v, vii) and prostate cancer (ii, iv, vi, viii) were stained with H&E, Dako (Rb.pAb anti-HER2), NeoMarkers (MAb anti-HER2), 
and ab-15 (MAb anti-EGFR). b) IHC staining of primary prostate cancer. c) Bone metastases from serial sections of TMA 85 with 
Dako and NeoMarkers antibodies. d) Two different patients' bone cores from TMA 85 stained with Dako and NeoMarkers 
antibodies. Inset boxes (ii, iv, vi, viii) are 1,000 magnification of 400 images (i, iii, v, vii). e) Tabulated summary of cellular 
distribution of HER2 staining on TMA 85 (4). 
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A 17-patient prostate cancer metastasis TMA (TMA 85) was stained with the Dako and 
NeoMarkers HER2 antibodies (Figure 3-1b, c). An intensity score (0–3) was assigned to the 
stained core by 2 board-certified genitourinary pathologists (R. Shah and L.P. Kunja). Shown in 
Figure 3-1d (core 1: i–iv and core 2: v–viii) are serial sections of two representative patients with 
bone metastasis from the metastasis array to characterize the cellular location of HER2 staining 
with these antibodies. Cellular localization of HER2 staining in the bone metastasis cores is 
described as cytoplasmic, membranous, or as a combination of both (Figure 3-1e). The Dako 
antibody exhibited primarily cytosolic staining in organ-confined disease (Figure 3-1b) and 
retained this pattern in bone metastasis (Figure 3-1c, d). Interestingly, the staining for the 
NeoMarkers antibody changed from a predominantly membrane pattern in early-stage disease 
(Figure 3-1b) to an intense cytosolic pattern in bone metastasis (Figure 3-1c, d). As in previous 
experiments, the NeoMarkers antibody appears more sensitive for the detection of HER2 in 
situ than the Dako antibody. FISH analysis was performed on TMA 85 and TMA 142, another 
prostate cancer array with 49 patients, to determine whether ERBB2 gene amplification was 
present. In agreement with the FISH analysis of radical prostatectomy specimens reported by 
Minner and colleagues (169), all 35 patients' TMAs had normal ERBB2 copy numbers, thus 
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eliminating gene amplification as a mechanism of HER2 and EGFR protein overexpression 
(Figure 3-2). 
3.4.2 The requirement of HER2 for osteoblastic growth 
To determine whether HER2 protein is required for the osseous growth of prostate cancer 
cells, we knocked down ERBB2 mRNA in C4-2B cells using lentiviral constructs containing 
ERBB2-specific shRNA sequences (shHER2) or scrambled HER2 sequences (scrVec). Reduction 
of ERBB2 was confirmed by Western blot analysis of shHER2 C4-2B cells compared with scrVec 
and parental (no transduction) control cells (Figure 3-3a). scrVec or shHER2 C4-2B cells were 
injected into the tibia of male SCID mice and allowed to grow for 5 weeks, at which time the tibiae 
were prepared for IHC analysis. The NeoMarkers antibody in scrVec and shHER2 tumors 
confirmed that the loss of HER2 expression was maintained in the knockdown xenografts in vivo 
(Figure 3-3b). EGFR levels were unchanged in these tumors. However, levels of the proliferation 
Figure 3-2 Fluorescence in situ hybridization analysis of ERBB2. Schematic diagram depicts the genomic organization of ERBB2 
on chr17q12: deletions (Del), amplifications (Amp), duplications (Dup). The red dot indicates the location of Chr. 17 centromere 
probe and the green dot is the location of ERBB2 locus on Chr17q12. BAC clone RP11-94L15 spanning 161kb on chr17q12 
contains ERBB2 gene (4). 
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marker, Ki-67, were reduced in parallel with 
the reduction in HER2 protein expression 
(Figure 3-3c), indicating reduced cellular 
proliferation in these bone xenografts. 
 
3.4.3  The role of EGFR and HER2 in 
prostasphere formation 
To determine whether HER2 or EGFR 
plays a regulatory role in the tumor-initiating 
component of prostate cancer metastasis, we 
quantified HER2 and EGFR cell surface 
expression in C4-2B cells by flow cytometry 
(Figure 3-4a). The amount of EGFR (260,000 
molecules/cell) on the cell surface was 10-
fold higher than HER2 (27,000 
molecules/cell) on C4-2B cells. This 
difference could be visualized by weak cell 
surface immunofluorescence using an HER2-
specific antibody (Figure 3-4b, i) compared 
with strong cell surface immunofluorescence 
using an EGFR-specific antibody (Figure 
3-4b, ii). We next examined sphere formation 
in cells that were selected from the top 5% of EGFR or HER2 surface expression in comparison 
A 
B 
C 
Figure 3-3 Characterization of HER2 knockdown in C4-2B 
prostate cancer intratibial xenografts. a) Western blot analysis of 
HER2 expression in C4-2B parental, scrVec, and shHER2 cells. E-
Cadherin was used as a loading control. b) SCID mouse model of 
tibiae injections of shHER2 versus scrVec C4-2B cells. 
Representative IHC of the tibiae at 3 weeks post injection using 
H&E, anti-HER2 (NeoMarkers), anti-EGFR, and anti-RANK. c) 
From these same mice tibiae, Ki-67 staining was assessed by 
counting 5x100 cells and using the average percent positive. *, P 
= 0.02 (4). 
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with cells selected for the lowest 5% of EGFR or HER2 surface expression. Only high EGFR 
expressing cells were able to produce primary spheres compared with the DAPI-negative or viable 
control cells (Figure 3-4c, d). In addition, the ability of C4-2B cells to form primary spheres was 
only reduced in low EGFR-expressing cells. There was no independent requirement for HER2 
expression for primary sphere formation, as HER2low cells were fully capable of sphere formation 
(Figure 3-4c, d). To confirm that high EGFR expression was important for the tumor-initiating 
potential of C4-2B cells, we performed secondary sphere formation assays, which validated the 
association of high EGFR protein on cell surface and the ability to form secondary spheres (Figure 
3-4c, d). Because sphere-propagating cells have been associated with tumor-initiating or stem cell–
like properties in prostate cancer cells (189-192), our findings support the idea that EGFR may 
mediate prostate cancer metastasis by supporting the TICs. 
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Figure 3-4 The impact of EGFR and HER2 levels on prostate sphere formation. a) Flow cytometric quantification of EGFR and 
HER2 molecules on the surface of C4-2B cells under normal growth conditions. b) Fluorescent microscopy of costained C4-2B 
cells: i, anti-HER2; ii, anti-EGFR; iii, EGFR and HER2 colocalization; and iv–vi, the respective staining backgrounds. c) C4-2B 
cells were sorted via flow cytometry for high or low expression of EGFR or HER2 (independently). The sorted cells were grown as 
primary and secondary prostate spheres and then quantified. Cells expressing low levels of EGFR were significantly inhibited in 
their capacity to form primary and secondary prostaspheres than cells expressing high levels of EGFR. The results represent the 
mean (n = 3) of 1 of 3 independent experiments. **, P ≤ 0.01; ****, P ≤ 0.0001; ns, not significant (P > 0.05). D, Brightfield 
photographs (x10) of the primary and secondary C4-2B prostaspheres as analyzed in C (4). 
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3.4.4 EGFR is expressed on CTCs from patients with bone metastasis 
CTCs may share important characteristics with cancer stem cells, such as the capacity for 
dormancy and the expression of a variety of growth factor receptors, including HER2 and EGFR 
(33, 170, 171, 177). To determine whether EGFR is expressed on CTCs in patients with prostate 
cancer bone metastasis, we isolated CTCs from whole blood samples taken from consented 
patients with prostate cancer using the microfluidic GO chip (115). An antibody against the 
epithelial cellular adhesion molecule (anti-EpCAM, R&D Systems) was used for CTC capture, 
and captured CTCs were then stained on-chip with primary antibodies against cytokeratin 7/8 
(CK), CD45, and EGFR (Figure 3-5c-e). The clinical characteristics of the 10 patients are 
described in Figure 3-5a. All patients exhibited metastatic disease with significant bone 
involvement. CTCs were present in all 10 patients and EGFR staining was detected on CTCs in 9 
of 10 patients. A median of 35.5% of CTCs were positive for EGFR staining (Figure 3-5b). 
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3.4.5 Dual inhibition of EGFR and HER2 is cytotoxic to C4-2B cells in culture and in intratibial 
xenografts 
The observation that EGFR protein expression was unchanged in viable HER2-knockdown 
cells coupled with the finding that reduction of EGFR expression was lethal in C4-2B cells 
suggested a role for EGFR in the survival of prostate cancer cells. C4-2B cells exhibited dose-
dependent sensitivity to the pan-ErbB tyrosine kinase inhibitor lapatinib over 48 hours (Figure 
3-6a). The efficacy of lapatinib and afatinib, a related EGFR/HER2 tyrosine kinase inhibitor, on 
the C4-2B cells was associated with a reduction of both HER2 and EGFR protein following 
treatment (Figure 3-6b). To further assess a dual role for HER2 and EGFR in survival, C4-2B 
Figure 3-5 Analysis of CTCs from 10 patients with metastatic prostate cancer. a) Clinical history of patients with prostate cancer 
analyzed for CTCs. b) Number of CK+/EGFR+ and CK+/EGFR- CTCs isolated per 1 mL whole blood. Numbers above the columns 
indicate the total number of CTCs isolated from patients 1–10. c) Cluster of white blood cells surrounding a CK+/EGFR+ CTC 
from patient 3. White blood cells stained positive for CD45. d, e) Other representative images of CK+/EGFR+ CTCs from patients 
3 and 5 respectively (4).  
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luciferase–expressing xenografts 
were established in NOD/SCID 
mice. Thirty-four mice were 
randomized into 3 treatment groups 
and monitored by bioluminescence 
over 7 weeks. Treatment with 
lapatinib or a combination of 
cetuximab (anti-EGFR) and 
trastuzumab (anti-HER2) resulted 
in smaller tumors at 7.5 weeks 
posttreatment (Figure 3-6c, e). 
Significant changes in the 
expression of several relevant 
biomarkers were also noted in the 
drug-treated xenografts (Figure 
3-6d). A reduction in HER2 and 
EGFR staining reflected target-
specific cytotoxicity of the C4-2B 
cells, whereas loss of CK8 and 
RANK revealed that these human 
tumor cells were completely 
depleted in the tibiae. We observed 
a near-complete reduction of cellular proliferation in the shHER2 C4-2B bone xenografts as 
Figure 3-6 Pharmacologic inhibition of HER2 and EGFR is cytotoxic to prostate 
cancer in vitro and prevents cancer growth in vivo. a) C4-2BLuc cell viability 
measured by Titer Blue following lapatinib treatment for 1, 24, and 48 hours. *, 
P < 0.05 compared with vehicle control. b) Left, Western blot analyses of HER2 
and EGFR expression in C4-2B cells following incubation with vehicle or 12.5 
μmol/L lapatinib at 24 and 48 hours. Right, Western blot analysis of C4-2BLuc 
cells after incubation with vehicle, 1 μmol/L, or 5 μmol/L afatinib for 24 hours. 
Tubulin was used as a loading control. Left, densitometry was performed with 
ImageJ. Right, fluorescence was measured using the Odyssey CLx (LI-COR) and 
quantified using Image Studio v3.1.4 software (LI-COR). Both, normalized to 
tubulin, values shown under respective lanes. c, d) C4-2BLuc cells were injected 
into mouse tibiae 1 week prior to treatments. Untreated mice (Control, n = 10), 
treated with lapatinib (n = 10), or treated with a combination of trastuzumab 
and cetuximab (TZB + CTX, n = 12) biweekly for 6 weeks. c) Bioluminescence 
of representative mice at the end of the study where i and ii are control, while iii 
and iv received dual inhibitor treatments. d) Serial sections of representative 
tibia stained with H&E, anti-pHist3, anti-CK8, anti-EGFR, anti-HER2, anti-
RANK, and anti-Ki-67. e) Quantitation of viable tumor cells was performed by 
counting three fields of anti-CK8–positive cells in areas that exhibited Ki-67 
positivity in three animals per group. No viable human tumor cells could be 
found in the lapatinib or in the TZB + CTX groups at 7.5 weeks. *, P < 0.0001 
(4). 
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reflected by loss of Ki-67 staining (Figure 3-6d, e). Positive staining for murine phospho-Histone 
H3 (pHist3) indicates that after treatment, there are still proliferating mouse cells in the marrow. 
The lack of EGFR- and HER2-positive cells suggests that ErbB targeting agents have very 
pronounced efficacy on prostate cancer in the tibia xenograft model. 
 
3.5 Discussion 
Metastatic prostate cancer is a deadly disease that initially responds to docetaxel-based 
chemotherapy and drugs that suppress androgen signaling. While these treatments may offer 
temporary relief, relapse is inevitable, and therapeutic options for treating patients who fail primary 
treatment are very limited. Thus, the search for new therapeutic strategies to treat advanced 
prostate cancer remains of paramount importance. A promising area of investigation focuses on 
inhibiting specific growth factor signaling pathways that directly support the metastatic 
progression of prostate cancer. Alterations in growth factor receptors or their downstream 
signaling components have been implicated in all human cancers; however, the role of these 
signaling pathways in the progression of prostate cancer has not been fully established. Agents 
that target these molecules with a high degree of specificity have been developed and tested in 
preclinical models and in clinical trials for prostate cancer with varying degrees of success. 
Previous studies of HER2 overexpression in multiple cancers have reported ranges from 
0% to 100% in IHC studies (193-196). These conflicting sets of data are most likely due to the use 
of different IHC assays and antibodies. Historically, HER2 overexpression has been determined 
solely by gene amplification and, because of this, protein levels of HER2 have not been extensively 
explored and characterized in prostate cancer progression. The histopathologic findings from this 
study demonstrated that the overexpression of both HER2 and EGFR proteins is associated with 
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prostate cancer progression and bone metastasis. While ERBB2 gene amplification does not appear 
to play a role in the etiology of localized prostate cancer progression (169), this had not been 
examined in metastatic prostate cancer. Hence, FISH analysis was used on both TMAs showing 
no instances of ERBB2 gene amplification, although the amplification of EGFR in prostate cancer 
metastasis remains unreported. Therefore, overexpression of HER2 protein may be sufficient to 
support the osseous metastasis of human prostate cancer. 
In addition, we found that EGFR was overexpressed in prostate cancer cells and that high 
EGFR-expressing cells preferentially formed prostaspheres. The knockdown of HER2 in C4-2B 
cells did not affect the levels of EGFR expression. Our attempts to knockdown EGFR were lethal 
to prostate cancer cells, which is not surprising, as these lethal EGFR knockdowns have been 
observed in a number of studies (197-199). Taken together, this suggests that EGFR may function 
in various aspects of prostate cancer progression including tumor maintenance and self-renewal. 
Several lines of evidence support this view, including the previous observations that the addition 
of EGF to defined media promotes stem cell maintenance (200) and that the activation of EGFR 
increases prostasphere formation (201). 
Recent studies suggest that CTCs may contain a highly enriched proportion of CSCs or at 
least exhibit many of the same characteristics (202). It will be critical to establish the molecular 
basis of the relationship between CTCs and CSCs. Of particular interest to us was the relationship 
between the role of EGFR in prostate TICs and survival of prostate CTCs. It is likely that diverse 
signaling pathways are required to maintain the cells in circulation and support them as they 
reestablish their growth at distant sites. There is an increasing body of evidence suggesting that 
EGFR and HER2 may play such a role (203, 204). This is supported by the finding that not only 
is EGFR protein expressed in metastatic prostate cancer (165) but also that it is required for sphere 
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formation in culture. Because of the described microfluidic isolation technology, we were also 
able to demonstrate that EGFR is expressed in CTCs of men with metastatic prostate cancer. 
The pivotal role of EGFR family members in multiple cancers has led to the development 
of targeted therapies, including therapeutic antibodies and small-molecule inhibitors. Targeting 
HER2-overexpressing breast cancers with trastuzumab, the therapeutic monoclonal antibody 
against HER2, has been proven efficacious. Treatment of HER2-expressing CRPC with 
trastuzumab had little response (clinical trial report NCT00003740). However, trials using 
cetuximab, erlotinib, and lapatinib have shown a variety of benefits in patients with prostate cancer 
who express these targets (NCT00728663, NCT00272038, NCT00103194; (205-207)). Low 
patient accrual, late stage of disease, and formation of various EGFR family dimers (affecting 
inhibitor binding) are some of the variables that may mask the true effectiveness of these drugs. 
Although some of the ErbB-specific therapeutics used in this study previously failed in the clinical 
setting, our results warrant further consideration for repurposing these compounds in combination 
with other modalities or in the selection of candidates based on ErbB status. 
In summary, we found that HER2 protein was elevated in CRPC bone. In addition, we 
observed that EGFR expression in bone metastasis was independent of HER2 status and was 
critical for sphere formation in the TIC component of these tumors and was present on the CTCs 
of patients with metastatic prostate cancer. The importance of HER2 and EGFR in the metastatic 
progression of prostate cancer was reflected in the mouse studies where only dual inhibition of 
both receptors inhibited tumor growth.  
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4.1 Abstract 
Bladder CTCs have the potential to serve as an alternative monitoring technique in a cancer 
that currently relies on cystoscopy. They could also provide details about potential therapeutic 
targets in a disease that has seen little improvement in the prognosis for late stage patients. 
However, their study has been limited by low detection sensitivity by the currently used 
technology. We proposed to isolated bladder using the graphene oxide chip with a combination of 
capture antibodies and to further probe these cells by staining for additional molecular markers of 
interest. These antibodies were optimized by first using bladder cancer cell lines and then by testing 
patient derived blood samples using optimized protocols. We detected CTCs in all five patients 
(range: 5-499 CTCs/mL), and additionally discovered clusters ranging in size from 2-39 
cells/cluster. We have observed EGFR+ and CD31+ CTCs, though no HER2+ or ADAM15+ 
CTCs. Future directions will involve accruing a larger cohort. 
4.2 Introduction 
Bladder cancer represents 5% of all new cancer diagnoses in the United States (208). Like 
prostate cancer, as the disease spreads, the five-year survival rate decreases (208). Staging and 
monitoring of the disease is difficult, with cystoscopy currently the gold standard (209). However, 
this technique has several major issues including the possibility of understaging the disease (210) 
and contributions to the high financial cost of bladder cancer (136). While there are a number of 
soluble protein biomarkers (209) as well as a fluorescence in situ hybridization based urine 
Chapter 4 Isolation of CTCs from metastatic bladder cancer patient samples 
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cytology assay (211), they still cannot supplant cystoscopy (212). There remains a need for a non-
invasive biomarker than can better inform disease progression. Circulating tumor cells (CTCs), 
which are accessible by “liquid biopsy,” could represent this alternative. 
Prior work in isolating and analyzing bladder CTCs mostly has been conducted using the 
macroscale CellSearch technology. An initial study was unable to detect CTCs in nonmetastatic 
patients and only had a 57.1% detection rate in metastatic patients (median: 2 CTCs/7.5 mL, range: 
0-79 CTCs/7.5 mL, (213)). A subsequent study was more successful. The overall success rate was 
36.4% (median: 2 CTCs/7.5 mL, range: 1-372 CTCs/7.5 mL), with CTCs detected in all five 
metastatic patients processed (214). Patients without CTCs showed significantly higher overall 
and progression free survival, while non-metastatic patients with CTCs had shorter disease specific 
survival. Other studies found that bone disease was more common in patients with CTCs and that 
patients with CTCs had short median survival, though the overall detection was still low: 27% 
(215). In general, low detection is a common thread amongst subsequent CellSearch studies, 
posting 18% (216), 21% (217), and 23% (218) in various cohorts. The last study also assessed 
HER2 expression on the isolated CTCs (218). Of the 22 patients with detectable CTCs, 14 
exhibited concordant HER2 expression with the primary tumor, though CTC HER2 status was not 
significantly associated with clinicopathologic features or outcomes. The RT-PCR based 
technique CELLection Dynabeads has been compared with the CellSearch technology, detecting 
CTCs in 44.4% of high-risk non-muscle-invasive bladder cancer patients in contrast with 
CellSearch’s detection rate of 19.8%. The presence of CTCs was significantly associated with both 
time to first recurrence and time to progression for both technologies (219). 
In addition to serving as a potential biomarker for monitoring, CTCs could also provide 
additional material to study with regards to molecular markers and pathways responsible for 
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metastasis. Of particular interest are leads on therapeutic targets as there has been little progress 
on improving the survival rates for advanced disease in over 30 years (135). Based on our previous 
work in prostate cancer (Chapter 3, (4)), we are particularly interested in the role of the epidermal 
growth factor receptors, specifically HER2 and EGFR, in bladder cancer progression. HER2 and 
EGFR have previously been associated with poor prognosis in bladder cancer (135) and preclinical 
results of an irreversibly inhibitor of the tyrosine kinase domains of EGFR, HER2, and HER4 have 
been promising (220). The analysis of CTCs may reveal in which steps of metastasis these 
receptors play a role, as well as whether different receptors are implicated in different steps.   
 Given the severe consequences when the disease spreads, we are also interested the 
mechanisms by which cancer cells enter and leave the blood stream as well as their interactions 
with cells in the blood. ADAM15 (A Disintegrin And Metalloproteinase) has emerged as an 
opportunity for intervention given its overexpression at the mRNA level in invasive and metastatic 
bladder cancer, strong staining in tissue arrays, and role in tumor cell invasion as shown through 
knockdown (221). Additionally, its multiple domains provide several promising targets for 
therapeutics (222), and preliminary cell line and xenograft experiments using novel ADAM15-
specific sulfonamide inhibitor have been highly successful (221). It is also worth noting that the 
metalloproteinase component of ADAM15 releases cell-bound ligands that ultimately bind to 
EGFR. 
Another potential contributor to the intermediate steps of metastasis is CD31 (also known 
as PECAM1). CD31 is more typically associated with endothelial cells (223), and, in the context 
of cancer, angiogenesis, however recent experimental results from the lab of Professor Mark L. 
Day have raised questions about its role in cancer cell migration. This led us to question the 
potential expression of CD31 in CTCs. 
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We sought to apply a highly sensitive nanomaterial based technology to the isolation of 
bladder CTCs to overcome previous issues of low detection exhibited by the CellSearch system. 
To further improve capture and increase sensitivity, we used antibodies against two cell surface 
markers: EpCAM and EGFR. Given that we used an image-based detection modality rather than 
PCR detection (as with CELLection Dynabeads), we also had the opportunity to investigate 
markers potentially associated with the steps of metastasis. 
4.3 Methods 
4.3.1 Cell culture 
The bladder cancer cell lines UM-UC-5, UM-UC-9, and UM-UC-18 were generously 
provided by the Day lab. Cells were maintained in DMEM (Gibco) supplemented with 10% fetal 
bovine serum (FBS, Sigma) and 1% antibiotic-antimycotic (Gibco). All cell lines were maintained 
in a 37°C incubator with 5% CO2. 
4.3.2 Preliminary antibody testing 
Antibodies were tested by staining cell lines deposited onto microscope slides. Cells were 
cytospun onto polylysine coated slides (Thermo Scientific) using a Cytospin 4 (Thermo Scientific). 
Four percent paraformaldehyde (PFA, Thermo Scientific) was applied to the slides using Cytospin 
as well. Slides were then permeabilized with 0.05% Triton X (Sigma) in phosphate buffered saline 
(PBS, Gibco) and blocked with 10% goat serum (Invitrogen). Most primary antibodies (Table 4-1) 
were incubated overnight at 4°C, though some of the tests of the HER2 antibodies were performed 
using a 1 hr room temperature incubation. After three washes, the secondary antibodies were 
applied, after which the slides were washed again three times. Coverslips were then mounted with 
ProLong Gold antifade reagent with DAPI (Molecular Probes). 
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4.3.3 Cell spike experiments and patient sample processing 
To verify our ability to capture bladder cancer cells on the GO Chip, cell spike experiments 
were performed using GO Chips fabricated and functionalized as previously described (115). All 
materials were introduced to the chip using a syringe pump (Harvard Apparatus). Following a PBS 
wash, an antibody solution of anti-EpCAM (R&D Systems) and anti-EGFR (Ray Biotech) in 1% 
bovine serum albumin (BSA, Sigma) was added to the chip, incubated, and washed off. The chip 
was then blocked with 3% BSA. 
For cell spike experiments, cells pre-labeled with CellTracker dye (Invitrogen) were spiked 
into whole blood provided by a healthy volunteer and flowed through the chip at 1 mL/hr. 
Following capture, the device was vigorously washed. Cells were fixed and permeabilized using 
Cytofix/Cytoperm (Fisher Scientific) and stain for their nuclei using 4',6-diamidino-2-
phenylindole (DAPI, Thermo Fisher). 
For patient samples, whole blood was collected from metastatic bladder cancer patients 
with informed consent under IRB HUM42401. Blood was flowed through the chip at 1 mL/hr. 
Two parallel chips were run for each patient to allow staining for all the markers of interest. The 
devices were then washed after which cells captured on-chip were fixed using 4% PFA. 
4.3.4 Staining 
0.2% Triton-X in PBS was used to permeabilize cells, after which blocking was conducted 
using 2% goat-3% bovine serum. Cocktails of primary antibodies (Table 4-1) were incubated on-
chip for 1 hr at room temperature, followed by the appropriate secondary antibodies, which were 
incubated for 1 hr at room temperature in the dark. Nuclei were labeled with DAPI. 
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Table 4-1 Antibodies used in capture and staining of bladder CTCs. Bold indicates antibodies used in chip staining, while black 
boxes indicate those used in the second round of staining. 
Purpose Antigen Host/Isotype Company Catalog No. Fluorophore 
Capture EpCAM Goat IgG R&D BAF960 N/A 
Capture EGFR Mouse IgG2b Ray Biotech MD-02-0006 N/A 
Staining 1° CD45 Mouse IgG2a BioRad MCA87GA N/A 
Staining 1° CD45 Rat IgG2b Santa Cruz Sc-70699 N/A 
Staining 1° CK 8/18 Guinea Pig Abcam ab194130 N/A 
Staining 1° CK 7/8 Mouse IgG2a BD 349205 N/A 
Staining 1° EGFR Mouse IgG1 ThermoFisher 2800005 N/A 
Staining 1° HER2 Rabbit Abcam ab134182 N/A 
Staining 1° HER2 Rabbit Santa Cruz sc-284 N/A 
Staining 1°/2° HER2 
(preconjugate) 
Mouse IgG1 BD 340554 APC 
Staining 1° HER2 Rabbit Cell Signaling 2165 N/A 
Staining 1° CD31 Mouse IgG1 R&D BBA7 N/A 
Staining 1° ADAM15 Rabbit Day Lab N/A N/A 
Staining 1° ADAM15 Rabbit Abcam ab124698 N/A 
Staining 2° Mouse IgG2a Goat ThermoFisher A-21131 AlexaFluor 488 
Staining 2° Rat IgG (H+L) Goat ThermoFisher A-11006 AlexaFluor 488 
Staining 2° Guinea Pig IgG 
(H+L) 
Goat ThermoFisher A-11075 AlexaFluor 568 
Staining 2° Mouse IgG2a Goat ThermoFisher A-21133 AlexaFluor 546 
Staining 2° Mouse IgG1 Goat ThermoFisher A-21240 AlexaFluor 647 
Staining 2° Rabbit IgG 
(H+L) 
Goat ThermoFisher SA5-10035 Dylight 755 
 
4.3.5 Imaging and analysis 
Imaging was conducted on a Nikon Eclipse Ti fluorescence microscope. Images were 
captured using a QImaging cooled mono 12-bit camera. Devices were first scanned at 10x for 
preliminary analysis, with 20x imaging conducted for locations requiring further clarification. 
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Analysis was conducted using NIS-Elements software. Those nucleated cells expressing CK but 
not CD45 (DAPI+/CK+/CD45- cells), were counted as CTCs. Cells were also analyzed for their 
expression of EGFR and HER2 on one chip and ADAM15 and CD31 on the other. 
4.4 Results 
4.4.1 Cell line spike experiments 
Given the high expression of EpCAM by intermediate and high grade bladder tumors (224) 
and our interest in EGFR, we performed capture with antibodies against those two moieties 
tethered to the GO Chip. To test the potential of the device to capture bladder CTCs, bladder cancer 
cell lines with differing expression patterns were fluorescently labeled and spiked into whole blood 
to simulate patient samples. Of the three cell lines tested (Figure 4-1), UM-UC-5 and UM-UC-9 
showed higher capture (average captures of 88.5% ± 8.2% and 90.7% ± 14.9%, respectively) than 
UM-UC-18 (average capture of 12.6% ± 3.3%). This is consistent with the higher expression of 
EpCAM and EGFR by UM-UC-5 and UM-UC-9 and the highly heterogeneous expression by UM-
UC-18. 
Figure 4-1 Capture efficiencies for bladder cancer cell lines on the GO Chip. Cell lines spiked into 
whole blood were captured at efficiencies consistent with their levels of antigen expression. 
 89 
 
 
4.4.2 Staining optimization 
To test antibodies for their ultimate application on-chip, staining was conducted on the 
three cell lines on microscope slides (example images, Figure 4-2). Combinations were selected 
that ultimately complied with the necessary combinations of isotypes and secondary antibodies 
and showed staining patterns consistent with previous cell line characterization. 
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4.4.3 CTC capture from bladder cancer patient samples 
A total of five patients (Table 4-2) and one healthy control were processed to determine 
CTC counts and a false positive threshold respectively (Figure 4-3, Table 4-3). The first three 
patients were stained for CK 8/18, CD45, and either EGFR and HER or CD31 and ADAM15. 
Figure 4-2 Examples of slide staining for antibody optimization. a) Staining for cytokeratin (CK) 8/18, EGFR, and HER2. b) 
Staining for CK 8/18, CD31, and ADAM15. CD45 staining not shown as these cell lines are negative for CD45. 
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CTCs were detected in all three patients (range: 5-499 CTCs/mL, Table 4-3). CD31+ CTCs were 
detected in a small percentage of cells in all three samples, while EGFR+ CTCs were detected in 
1/3 samples (Figure 4-4a, b). ADAM15 and HER2 were not observed to be expressed in any of 
the captured CTCs. Clusters were observed 
in 2/3 samples, with one sample (9058) 
showing a particularly high number and 
size of clusters (Figure 4-4c-e, Figure 
4-5). Between 0 and 42% of CTCs were 
present in clusters (median: 9%). 
However, the high presence of 25 
CK+ cells/mL in the healthy control was a 
concern, leading us to shift to staining for 
CK 7/8 due to possible issues with CK 18 
expression by white blood cells. Two subsequent samples were stained using CK 7/8 with a 
different CD45 to account for the change in host/isotype of the cytokeratin antibody, as well as 
with the same antibodies for EGFR, HER2, CD31, and ADAM15 (Figure 4-7, Figure 4-6). Once 
again, CTCs were captured from both samples, with CD31+ and EGFR+ CTCs observed. Only 
one cluster, a doublet, was observed across the four chips. 
  
Figure 4-3 Experiment schematic for bladder cancer CTC capture and 
staining workflow. 
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Table 4-2 Bladder cancer clinical cohort. C = carboplatin. G = gemcitabine. P = pembrolizumab. MVAC = 
methotrexate/vinblastine/doxorubicin/cisplatin. 
Number of patients 5 100% 
Age   
Median (range) 73 (70-78) 
Sex   
Male 4 80% 
Female 1 20% 
Race   
Caucasian 5 100% 
Performance status   
0 0 0% 
1 4 80% 
2 0 0% 
3 1 20% 
Cystectomy 2 40% 
Metastatic disease 5 100% 
Lymph node metastases 3 60% 
Visceral metastases 4 80% 
Bone metastases 1 20% 
Therapy   
Atezolizumab 1 20% 
C/G 1 20% 
C/G/P 1 20% 
MVAC 1 20% 
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Table 4-3 Patient sample enumeration in metastatic bladder cancer patient samples. 
 
Staining, round 1 (CK 8/18) 
Sample Total CK+/CD31-/ADAM15- CK+/CD31+/ADAM15- Single cells Cells in clusters 
8668 143 142 1 143 0 
9057 29 27 2 27 2 
9058 410 370 40 262 148 
Sample Total CK+/EGFR-/HER2- CK+/EGFR+/HER2- Single cells Cells in clusters 
8668 5 5 0 5 0 
9057 38 38 0 34 4 
9058 499 491 8 287 212 
Staining, round 2 (CK 7/8) 
Sample Total CK+/CD31-/ADAM15- CK+/CD31+/ADAM15- Single cells Cells in clusters 
9059 3 3 0 3 0 
9060 8 7 1 8 0 
Sample Total CK+/EGFR-/HER2- CK+/EGFR+/HER2- Single cells Cells in clusters 
9059 5 4 1 8 0 
9060 7 7 0 5 2 
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Figure 4-4 Enumeration results from the first round of chip staining. Devices from three patient 
samples were stained for CK 8/18 and CD45 as well as either CD31 and ADAM15 (a, c) or EGFR 
and HER2 (b, d). CTCs were enumerated based on their staining patterns (a, b). The percentage of 
CTCs present as clusters was also determined (c, d). e) Clusters across the six stained chips ranged 
in size from 2 to 39 cells/cluster, with the majority of clusters comprising lower numbers of cells. 
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Figure 4-5 Examples of clusters from the first round of staining. Scale bar = 10 μm. 
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Figure 4-7 Enumeration results from the second round of chip staining. Three patients were stained for CK 7/8 and CD45 as well 
as either CD31 and ADAM15 (a, c) or EGFR and HER2 (b, d). CTCs were enumerated based on their staining patterns (a, b). The 
percentage of CTCs present as clusters was also determined (c, d). 
Figure 4-6 Example CTCs from the second round of 
staining. Scale bar = 10 μm. 
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4.5 Discussion 
The interrogation of CTCs in bladder cancer has been thus far limited by insufficient 
detection sensitivity. By using a highly sensitive microfluidic technology, CTCs were detected at 
higher than healthy control threshold on 9/10 chips processed. These preliminary results suggest 
that further investigation is warranted into these cells on the path to metastasis. 
In addition to detecting CTCs, recent equipment upgrades have allowed us to ask specific 
questions about molecular markers potentially implicated in metastasis. In contrast to our previous 
work in prostate cancer, we were able to assess the presence of both HER2 and EGFR rather than 
picking only one of the markers. Interestingly, only EGFR was observed in the CTCs captured 
from two of the five patients processed here. This is consistent with previous hypotheses that 
EGFR may be responsible for tumor initiation and survival in transit while HER2 plays more of a 
role in cell proliferation at established sites (4), though it conflicts with previous reports of HER2 
positive CTCs in bladder cancer (218). Given previous reports and other staining results, we will 
continue to explore antibodies for HER2. However, given the existence of many therapies that 
target EGFR, this is a promising observation due to the need of therapeutic options for advanced 
bladder cancer patients. 
To our knowledge, this is the first example of the isolation of CD31 positive CTCs. CD31+ 
cells have been previously isolated from colorectal cancer patients using a filtration-based 
technology, though those cells were determined to be endothelial cells (225). However, the cells 
isolated in our study were required to stain positive for cytokeratin, allowing us to make this 
distinction. Investigation into these tumor cells may shed light on the metastatic process as well as 
cellular interactions in transit. 
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We have optimized the protocols and reagents best able to study our hypotheses regarding 
the role HER2, EGFR, CD31, and ADAM15 in metastasis and processed five patient samples thus 
far. To draw significant conclusions, more patient samples will need be processed. The data drawn 
from that study may be used for comparison with cell line and animal models of bladder metastasis. 
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5.1 Abstract 
Challenges to clinical applications of CTC include limitations placed on downstream 
analysis. In particular, immunocapture techniques offer high sensitivity, but are often hamstrung 
by the tethering of cells to capture surfaces. Two techniques are discussed to improve on one such 
immunocapture technology, the GO Chip, by incorporating graphene (GO) oxide into microfluidic 
devices in conjunction with polymers than may either be degraded or dissolved. Early attempts to 
build polymer-GO films through layer-by-layer (LbL) assembly failed to simultaneously retain the 
high capture efficiency and low nonspecific binding of the GO Chip. Ultimately, a microfluidic 
device incorporating a drop-cast thermosensitive polymer-GO film as the substrate for antibody 
capture allowed for sensitive capture (up to 95.21%) and efficient release (91.56% in blood-based 
samples). Clinical applicability of the device was demonstrated through processing 10 breast 
cancer patient samples and 3 pancreatic patient samples. Potential for downstream analysis was 
exhibited by performing fluorescence in situ hybridization to detect HER2 amplification in CTCs 
from one breast cancer patient. The validation of this device represents preliminary steps to 
resolving a current drawback in many CTC isolation technologies. 
5.2 Introduction 
CTCs not only provide biological insight into primary and metastatic tumors but also have 
the potential to serve as real time biomarkers for making treatment decisions and monitoring drug 
efficacy (15). Indeed, over 270 clinical trials have now been proposed using CTCs as surrogate 
Chapter 5 GO 2.0: strategies to release captured CTCs from the GO Chip 
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biomarkers (226). However, to date, CTCs have not been incorporated into clinical practice for 
management of patients with cancer. The main challenges to this field include: (i) reaching the 
sensitivity needed to isolate these extremely rare cells from the surrounding blood cells (1 in 1 
billion), (ii) minimizing processing to preserve the viability of cells, and (iii) achieving the 
specificity necessary to acquire pure population to enable meaningful genomic and functional 
analysis. 
A graphene oxide (GO) based CTC capture device, the GO Chip, took advantage of the 
increased surface area afforded by graphene oxide for highly sensitive and selective cell capture 
(as described in Chapter 2, Chapter 3, (227)). However, most immunoaffinity based technologies 
conjugate capture antibodies to either a substrate surface, as is the case with the GO Chip, or three 
dimensional features. Consequently, the purified CTCs remain within these technologies after 
capture. This limits post-capture analysis because of difficulty in releasing viable cells from the 
capture substrate.  
5.2.1 Previous release technologies 
A number of different methods have been tried for the release of captured cells. Substrates 
coated with a “sacrificial layer” of hydrogel have been used to release cells upon the degradation 
of the surface to which the cells are adhered. An early generation of this method used cation 
chelation to disrupt an alginate hydrogel (228), but this prevented the processing of blood that had 
been stored in the presence of the anticoagulant EDTA. Cross-linked alginate hydrogels that could 
be degraded with alginate lyase allowed the processing of EDTA treated blood (229), However, 
the major drawback of this device was flow rate at which blood was processed (2 μL/min), making 
it unsuitable for routine implementation for analyzing clinical specimens. A method for the 
efficient and clinically compatible sample processing followed by cell release is still lacking. An 
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alternative approach for cell release is the temperature sensitive deconstruction of a biotinylated 
gelatin-streptavidin layer-by-layer (LbL) film (230). The capture agent was ultimately conjugated 
through a layer of nanoparticles, and this system allowed both the bulk release of cells by raising 
the temperature to 37°C or the release of individual cells through stimulation with a frequency-
controlled 80-μm microtip. This technology demonstrates the promise of temperature sensitive 
materials for use in cell release. 
Hou et al. used a thermoresponsive copolymer of N-isopropyl acrylamide and 3-
aminoethyl methacrylate grafted on to a silicon nanowire substrate and carrying anti-EpCAM 
antibodies as cell capturing agent for the capture and stimulated release of CTCs (231). This 
methodology was then incorporated in a microfluidic system that could subsequently be used to 
process blood samples (120). The system was optimized with respect to capture and release 
efficiency, but the throughput is not yet high enough and requires two rounds of sample processing 
to yield sufficient purity to conduct efficient whole genome amplification for downstream 
genetic/mutational analysis. Additionally, the process of fabricating nanofeatures on the silicon 
substrates is again a rate limiting step and requires access to expensive tools and clean room 
facilities. Liu et al. developed a similar approach for cell capture through hydrophobic interactions 
which could be thermally switched between capture and release mode (232). However, the 
limitations include static capture rather than a flow through system, time consuming surface 
grafted polymerization, and the need for experiments to be conducted at 37° C.  
These previously-explored approaches all feature performance limitations in throughput 
(233), purity requiring additional processing (120), the ability to process blood collected by 
standard conditions (234), immense fabrication facility requirements (120, 231), time-consuming 
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chemistry (235), and inconvenient experimental temperature conditions (235). There remains a 
need for a manageable and convenient yet high performing CTC capture/release technology. 
5.2.2 Strategies for cell capture/release devices incorporating graphene oxide 
5.2.2.1 Layer-by-Layer (LbL) fabrication enabled GO Chip (LbL GO Chip) 
While the graphene oxide (GO) Chip affords excellent sensitivity and selectivity, its utility 
in CTC analysis is hindered by the opaque capture surface and inability to release captured cells. 
Altering this device to eliminate the gold-patterned silicon foundation would remove an obstacle 
to superior imaging. This modification would also eliminate many expensive clean room 
fabrication steps, and greater functionality would be enabled through the incorporation of a 
degradable polymer. 
Layer-by-Layer (LbL) is a self-assembly method by which layers are sequentially 
deposited on a surface, and the integrity of the resulting composite is a function of the interactions 
between the layers. Various forces between layers of differing composition have been exploited 
and include electrostatic interactions, hydrophobic interactions (236), van der Waals forces (237), 
hydrogen bonding (238), acid/base reactions (239), and a host of chemical reactions such as click 
chemistry (240).  Films feature both lateral and vertical growth during assembly, and there is 
interpenetration between layers, creating a composite that draws from the properties of the 
individual layers. There is precedent for the use of graphene oxide in LbL films (241-244), 
inspiring our approach to use this method as the basis for a transparent graphene oxide circulating 
tumor cell capture/release device. 
Device construction largely followed the techniques used to build the GO Chip (115). To 
make the original GO Chip, GO is assembled on the substrate when a gold-patterned piece of 
silicon is dipped in a GO suspension. The mechanism behind this involves the electrostatic 
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attraction of the TBA to a monolayer of hydroxide ions formed on the gold patterns (245). The 
similarity between this process and LbL self-assembly inspired the protocol used for the 
fabrication of the transparent GO cell capture/release device. To make the LbL GO Chip, 
alternating layers of cationic and anionic polymer or graphene oxide based suspensions were 
deposited, also assembling based on electrostatic attraction. Graphene oxide suspensions were 
preparing similarly to that used in the original GO Chip, allowing them to serve as the basis for 
the same conjugation chemistry. Through this analogous process, it was hypothesized that device 
featuring the advantage of the original GO Chip could be fabricated while simultaneously 
addressing its disadvantages. 
5.2.2.2 Incorporation of a thermosensitive polymer 
Thermoresponsive polymers, a class of stimuli-responsive polymers that respond to 
temperature changes by undergoing conformational changes, have found wide applications in drug 
delivery (246), tissue engineering (247), controlling cell adhesion (248) and bacterial growth 
(249), protein encapsulation (250), and the release of captured CTCs from the surface of such 
capturing devices (231, 232). 
Graphene- and graphene oxide (GO)-based polymer composites are a new class of 
materials which combine the excellent properties of graphene, such as high surface-to-volume 
ratio, high Young’s modulus, and high thermal and electrical characteristics (251), with the easy 
processability of polymers. Such composites have found uses in fields ranging from energy storage 
(252) and electronic devices (253, 254), to biomedical applications such as drug and gene delivery 
(255, 256), cancer therapy (257), cell differentiation (258, 259), coating of biomedical implants 
(260, 261),  and bio-imaging (256).  
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The combined advantages of a biocompatible functionalized nanomaterial with a 
thermoresponsive polymer that promotes effective cell release could address the challenge of 
sensitive capture while simultaneously allowing viable cell release. This could lead to 
improvement in downstream analysis such as fluorescence in situ hybridization (FISH), molecular 
analysis, and single cell analysis. This chapter ultimately presents a tunable thermal-sensitive 
polymer-GO Chip for highly efficient capture and subsequent release of CTCs incorporated into a 
microfluidic device (3). 
5.3 Methods 
5.3.1 LbL device methods 
5.3.1.1 Materials and solutions 
LbL consists of alternating layers of anionic and cation suspensions, different combinations 
of which were used throughout this study. Anionic or negatively polar solutions included graphene 
oxide (GO, cheaptubes.com)-phospholipid polyethylene glycol amine (PEG, NOF America), 
sodium hyaluronate, and heparin. Cationic solutions included GO-tetrabutyl ammonium (TBA, 
Sigma-Aldrich) poly(ethyleneimine) (PEI, Sigma-Aldrich), and poly(diallyldimethylammonium 
chloride) (PDDA, Sigma-Aldrich). 
To prepare the GO-PEG suspension, GO powder was probe tip sonicated in 10-3 M NaCl 
at a concentration of 0.1% w/v GO for 1 hour, after which it was allowed to settle for two days. 
The supernatant was removed and centrifuged for 40 minutes at 3000 rpm. To make the GO-TBA 
suspension, 10 mg GO was added to 10 mL DI water along with 300 μl 40% TBA hydroxide and 
was probe tip sonicated for 30 minutes. For both suspensions, PEG was then added at a 
concentration of 3.75 mg/mL and bath sonicated for one hour, after which the suspension was 
centrifuged for three minutes at 12000 rpm; the supernatant was reserved for use in LbL. 
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All solutions were prepared through dilution and/or pH adjustment. PEI stock was diluted 
to 0.5 wt% PDDA was diluted to 2.0% (w/v). Hyaluronate was dissolved in 0.15 M NaCl to a 
concentration of 1 mg/mL; the solution pH was then adjusted to 4.5 using acetic acid. Heparin was 
dissolved in DI water to a concentration of 1 mg/mL. 
5.3.1.2 Film formation and device fabrication 
The LbL protocol was largely based on previous methods (241). Glass slides were first 
cleaned by sonication in a solution of HCl and Nochromix®. A polydimethyl siloxane (PDMS) 
reservoir was then reversibly attached to the clean glass slide and a preliminary layer of cationic 
solution was pipetted into the reservoir. The 
solution was incubated for 15 minutes and then 
washed out of the reservoir. The reservoir was 
then filled with an anionic solution and 
incubated for 15 minutes. This was again 
followed by a wash. This protocol was repeated 
until the desired number of layers was 
deposited (Figure 5-1). The reservoir was removed and the substrate was dried with house air. A 
PDMS chamber was then bonded on to the slide using a corona discharge and incubated on a hot 
plate at 85°C for 10 minutes. To functionalize, N-γ-maleimidobutyryloxy succinimide ester 
(GMBS, Thermo Scientific) was injected into the devices and incubated for 30 minutes. Tubing 
was inserted to allow the performance of all subsequent steps by syringe pump. The device was 
washed with ethanol, then NeutrAvidin (Thermo Scientific) was flowed and incubated for 40 
minutes. The device was then stored at 4°C until use. 
  
Figure 5-1 LbL protocol schematic. 
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5.3.1.3 Alternative conjugation chemistry 
As an alternative to the GMBS crosslinker, N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC, Sigma-Aldrich) N-hydroxysulfosuccinimide (sulfo-NHS, 
Thermo Scientific) chemistry was attempted. 40 mM EDC in 2-(N-morpholino)ethanesulfonic 
acid (MES) buffer was added to the PDMS reservoir after film formation and incubated for 15 
minutes on an orbital shaker. Then 10 mM sulfo-NHS in MES buffer was added and incubated for 
15 minutes on an orbital shaker. After three five-minute phosphate buffered saline (PBS, Gibco) 
washes on the orbital shaker, NeutrAvidin was added at a concentration of 100 μg/mL and 
incubated for three hours, followed by three additional five-minute PBS washes. 
5.3.1.4 Cell spike experiments 
Prior to sample flow, devices were coated/functionalized with anti-EpCAM (R&D 
systems) and were blocked with 3% bovine serum albumin (BSA, Sigma) in PBS. Cancer cell line 
cells prelabeled with CellTrackerTM dye (ThermoFisher Scientific) were counted and spiked into 
blood or buffer to evaluate the ability of the device to capture different cell types at various 
concentrations. Buffer experiments allow the determination of accurate capture efficiencies 
through mass balance while blood experiments provide purity metrics. The formulated samples 
were flowed through the devices at 1 mL/hr, followed by washing and fixation. For blood-based 
samples, cells were also permeabilized and labeled with 4,6-diamidino-2-phenylindole (DAPI, 
ThermoFisher Scientific). Devices were then scanned using a Nikon Eclipse Ti fluorescence 
microscope for subsequent counting and analysis. 
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5.3.2 Thermoresponsive polymer-GO device methods 
5.3.2.1 Polymer synthesis 
N-acryloyl piperidine was synthesized through reaction between acryloyl chloride (Fluka) 
and piperidine (Aldrich) (262). In short, 0.11 mol of piperidine and 0.12 mol of triethylamine were 
dissolved in 100 mL of dichloromethane maintained at 0-5° C. A solution of acryloyl chloride 
(0.10 mol) in 15 mL of dichloromethane was added drop-wise to the above solution over two hours 
under constant stirring. After complete addition, the reaction mixture was stirred at room 
temperature for 24 hours and was extracted with water and purified by column chromatography 
(hexane:ethyl acetate, 1:1) to yield colorless to light yellow liquid. N,N-diethylacrylamide (TCI 
America) was passed through a basic alumina column (Aldrich) prior to polymerization. AIBN 
(Aldrich) was recrystallized from methanol before use. In a typical polymerization reaction, the 
required amount of monomers was dissolved in anisole (Aldrich) and 0.3 mol% (of total monomer 
content) of AIBN was added to the solution. The reaction flask was completely sealed and the 
solution was purged with Argon for 20 minutes. The reaction was carried out at 65° C for 20 hours. 
After the reaction, all the solvent was evaporated at high temperature under vacuum to obtain white 
solid residue. The residue was re-dissolved in chloroform and then twice precipitated in ethyl 
acetate to obtain white solid mass. The precipitate was recovered and dried at 60° C under vacuum 
for 2-3 days. 
5.3.2.2 Polymer characterization 
The synthesized polymers were characterized by gel permeation chromatography (GPC, 
Waters Inc., 1515 Isocratic HPLC pump and 2414 RI detector) using three Styragel columns –  
HR2, HR3 and HR4 – in series maintained at 35° C with chloroform as eluent (flow rate: 1 mL/min, 
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total elution time: 40 min). The instrument was calibrated with polystyrene standards. LCST was 
ascertained by measuring UV-vis transmittance (Varian Cary 50 Bio) of a 0.1 wt.% aqueous 
solution of polymers as a function of temperature. A thermocouple was used for real-time 
measurement of temperature, with the metal junction dipped in the cuvette during the 
measurement. For effective measurement, the polymer solution was cooled down to 2-3° C along 
with the metal cuvette holder to slow down the heating up of sample in ambient condition. CaCl2 
was placed inside the UV-vis spectrophotometer chamber to ensure humidity-free environment. 
This was necessary to prevent atmospheric water vapor from condensing on the cold cuvette walls. 
UV-vis spectrum was measured from 200-800 nm at every 0.2-0.5° C with more frequent 
measurements near the transition temperature. Transmittance at 400 nm was plotted against 
temperature and the temperature for 50% transmittance was noted as the LCST. Molecular weights 
and LCSTs of different polymer batches were noted (Table 5-1). 
Table 5-1 Molecular weights, polydispersity index (PDI), and lower critical solution temperature (LCST) of different batches of 
synthesized polymers used in the study (3) 
Polymer Mn (kDa) Mw(kDa) PDI LCST (°C) 
P1 209.246 308.086 1.47 13.6 
P2 151.332 253.380 1.67 12.7 
P3 175.085 255.778 1.46 12.0 
P4 173.019 303.009 1.75 11.8 
 
5.3.2.3 Determination of amine surface availability 
To show the surface availability of the amine groups from the GO-PEG in polymer-GO 
composite films, the drop-cast films were incubated with 0.25 mM aqueous solution of an amine 
reactive dye, 5-(and-6)-carboxyfluorescein, succinimidyl ester (FSE; Life Technologies) for 30 
minutes at 40° C and then washed with copious amount of DI water. The dye treated films were 
then imaged with fluorescence microscope (Olympus BX51 coupled with Olympus DP71 camera 
and EXFO X-cite Series 120 light source). 
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5.3.2.4 Device fabrication 
The glass slides (Fisher) were sequentially washed with chloroform, acetone, and 
isopropanol via sonication for 5 minutes each. The glass slides were then air dried and treated in a 
UV-ozone generator for 30 minutes to remove any carbon contamination and to obtain a high 
density of surface hydroxyl groups. The cleaned substrates were patterned using Kapton polyimide 
tape (Cole Parmer) by masking the active device area. Kapton tape was chosen for its 
impermeability to silane vapors and good stability at high temperatures. The patterned substrates 
were then cleaned with wipes dipped in ethanol to remove any adhesive residue and treated with 
(Heptadecafluoro-1,1,2,2-tetrahydrodecyl)trichlorsilane (HFTCS, Gelest Inc.) via vapor phase 
surface modification at 100°C for 30 minutes. HFTCS treatment resulted in hydrophobic 
fluoroalkyl groups on the unmasked peripheral regions of the substrates. After HFTCS treatment, 
the Kapton tape mask was removed and the glass slides were washed with copious amounts of 
ethanol to remove any physisorbed silane as well as any adhesive residue. The second surface 
modification was done in liquid phase by immersing the glass slides in 3.35 mM 2-
methoxy(polyethyleneoxy)propyltrimethoxysilane (PEG-silane, Gelest Inc.) in ethanol for 12-15 
hours. Poly(ethylene glycol) (PEG) is well known to render surfaces non-fouling (263). The PEG 
monolayer was necessitated to avoid recapturing of the released CTCs on the glass substrate. 
Subsequently, the glass slides were again washed with ethanol to remove any physisorbed silane. 
A polymer-GO blend solution containing 10 mg/mL of polymer in 975 μL DMF and 25 μL of GO-
PEG solution (functionalized using a previously described chemistry (115)) was then drop-cast in 
requisite amount on the surface modified glass substrates and allowed to dry at 60°C in an oven 
for 2-3 hours to yield 3-4 m thick composite film. The PDMS chamber was assembled on the 
glass substrate with the polymer-GO composite film through corona discharge to produce a 
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microfluidic device (Figure 5-2). The device was functionalized by immobilizing anti-EpCAM on 
the surface available GO-PEG through a cross-linker (N-γ-maleimidobutyryl-oxysuccinimide 
ester, sulfo-GMBS) and avidin-biotin mediated bio-conjugation, providing cell capture/release 
functionality (Figure 5-3). 
Figure 5-2 Schematic for CTC device fabrication (3). 
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Figure 5-3 Thermosensitive polymer-GO CTC capture/release device. a) Schematic concept of a polymer-GO microfluidic device 
for the capture/release of CTCs. b) Enclosure within polydimethylsiloxane chamber and photograph of patient blood samples being 
processed by the polymer-GO devices (3). 
5.3.2.5 Fluorescent biotin assay 
To verify the ability to immobilize biotinylated antibody to the polymer-GO film surface, 
surface coverage by a fluorescently labeled biotin (Biotin (5-fluorescein) conjugate, Sigma 
Aldrich) was assessed (Figure 5-4). Three polymer-GO films underwent the entirety of the 
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conjugation chemistry (i.e. treatment with the GMBS cross-linker and NeutrAvidin; termed 
“Condition”) with fluorescent biotin addition as the terminal step. To account for non-specific 
binding, three polymer-GO films were treated only with the fluorescent biotin to serve as a control 
in an analogous fashion to an isotype control (termed “Control”). ImageJ was used to quantify the 
fluorescence. 
 
Figure 5-4 Fluorescent biotin assay. a) Schematic represents fluorescent biotin assay and negative control. b) The full conjugation 
chemistry features statistically higher fluorescence than the negative control as assessed via optical density (p = 0.019 (3)). 
5.3.2.6 Sample processing 
Following the introduction of anti-EpCAM to the device and blocking with 3% BSA, cell 
spike samples or patient samples were flowed on the chip. After washing with room temperature 
PBS, captured cells were released from the device by maintaining the device on ice and flowing 
cold PBS at a flow rate of 100 μl/min.  
To prepare cells for staining, the effluent could be cytospun onto Polysine Microscope 
Adhesion Slides (Thermo Scientific). Slides were stained for 4,6-diamidino-2-phenylindole 
(DAPI), anti-cytokeratin 7/8 (BD), and anti-CD45 (BD). Primary antibodies were labeled with 
fluorescence tagged secondaries (AlexaFluor 546 and AlexaFluor 488, Invitrogen). 
To prepare the cells for fluorescence in situ hybridization (FISH), CTCs released from the 
chip were subsequently made into “cell blocks” by first fixing them with ethanol and then 
embedding them in Histogel (Thermo Scientific). Blocks were then formalin fixed and stored in 
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70% ethanol until slide preparation. Blocks were paraffin embedded and sectioned at the 
University of Michigan Histology Core. FISH was conducted using probes for HER2 (BAC clone 
RP11-94L15) and chromosome 17 control probe (BAC clone RP11-100E5). FISH hybridization 
and image capture were performed essentially as previously described (264). 
5.4 Results 
5.4.1 LbL results 
While films of various compositions with various numbers of layers produced from this 
combination initially showed good capture results (Figure 5-5), these results were difficult to 
repeat (Table 5-2). Additionally, running spike experiments using the preliminary films 
incorporating PDDA in whole blood rather than buffer revealed issues of nonspecific binding for 
some conditions. In this instance, high nonspecific binding was defined as too high for the device 
to be useful for downstream genetic analysis. Oftentimes it was too high to be counted by the 
computer software, which in addition to being highly indicative of the failure of the device to be 
useful made it difficult to obtain reportable purity metrics. To combat these initial issues, 
conditions were attempted that included polymers chosen for their prior incorporation in anti-
adhesive coatings, hyaluronate and heparin (265). While use of NaHyaluronate in the anionic 
Figure 5-5 The LbL device. a) A ten layer PDDA/GO-PEG coated glass slide (left) contrasted with an uncoated glass slide (right). 
b) Example of an assembled device. c) Examples of captured cells on-chip. Cells exhibiting green fluorescence and blue nuclei are 
spiked in MCF-7 cancer cells, while cells with only the nuclei labeled are nonspecifically bound white blood cells. 
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solution mitigated the nonspecific binding issues, devices with that film composition failed to 
reliably capture cells at a sufficient efficiency for further investigation. Additionally, devices 
frequently leaked due to bonding issues. 
Table 5-2 Attempted experimental parameters for the LbL device. PDDA = poly(diallyldimethylammonium chloride), PEI = 
poly(ethyleneimine), PEG = phospholipid-polyethylene glycol-amine, TBA = tetrabutyl ammonium. 
Anionic 
solution 
Cationic 
 solution 
PEI Numbers of 
bilayers 
Maximum capture 
efficiency obtained 
Nonspecific 
binding 
GO-PEG PDDA As final layer for 
some trials 
1, 3, 5, 10 102% (higher than 
GO Chip control) 
High 
NaHyaluronate GO-PEG-TBA Used to precoat 
slides for some trials 
1, 3, 5, 10, 15 88.3% (unable to 
repeat this result) 
Low 
Heparin GO-PEG-TBA None 1 69% High 
Due to the upfront issues with achieving the required balance of high capture efficiency 
and low nonspecific binding during the capture step, this project did not make it to the phase during 
which release would have been attempted. 
5.4.2 Thermoresponsive polymer-GO device results 
5.4.2.1 Tunable thermoresponsive polymer 
To create a tunable thermal responsive polymer, copolymer poly(N-acryloyl piperidine-co-
N,N-diethyl acrylamide) was synthesized via free radical polymerization using AIBN as an 
initiator and was characterized for its molecular weight and LCST (Figure 5-6a). LCST was 
modulated by employing a copolymerization technique using two acrylamide monomers with 
different degrees of hydrophobicity: N-acryloyl piperidine (AP) and N,N-diethyl acrylamide 
(DEA). The homopolymers poly(N-acryloyl piperidine) (PAP) and poly(N,N-diethyl acrylamide) 
(PDEA) have LCSTs of 4° C and 25° C respectively (266). The required capture/release 
modulation temperature for the CTC device can be achieved by changing the ratio of the two 
monomers in the copolymer. For example, a copolymer synthesized with 7:3 molar ratio of 
AP:DEA showed a critical temperature of around 12-13oC, which was used in this study (Figure 
5-6b). 
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5.4.2.2 Film characterization 
To determine surface availability of 
the amine groups within the polymer-GO 
composite, films were incubated with a 
fluorescent amine fluorescent dye. While 
polymer-GO composite films showed bright 
green fluorescence from the surface tethered 
dye, polymer-only films showed very low to 
no fluorescence (Figure 5-6d). Though the 
possibility of physically adsorbed dye 
molecules cannot be completely ruled out, it is 
most likely that the dye molecules were 
primarily tethered to the surface through 
covalent bonding between the amine groups 
on film surface and succinimidyl ester groups 
on the dye, as suggested by large contrast in 
fluorescence intensity from polymer-GO and 
polymer-only films.  
Time dependence of dissolution of 
polymer-GO composite films in cold water 
was also determined. Dye treated films were 
dipped in cold water for different lengths of 
Figure 5-6 Polymer characterization. a) Synthetic scheme for 
copolymer. b) UV-vis transmittance vs temperature plots for the 
copolymer showing LCST of ~12° C. c) SEM image of polymer-
GO composite surface. Arrows indicate suspended GO present on 
the surface of the film. d) Fluorescence images of polymer-only 
and polymer-GO films. The films were incubated with an amine-
reactive dye (FSE, 0.25 mM aq. solution) for 30 minutes at 40° C. 
Scale bar: 20.0 μm (3). 
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time and the fluorescence images before and after dipping were compared. Films were dipped in 
cold water (5°C) for 5, 10, 20, and 30 minutes, and in room temperature water (20°C) for 30 
minutes. The beakers with the dipped films were kept on an orbital shaker to weakly simulate 
conditions in microfluidic devices where the films are subjected to shearing by the flowing fluids. 
While the film was completely dissolved and washed off in 20 to 30 minutes under cold condition, 
as evident from gradual disappearance of green fluorescence, it remained stable and intact at room 
temperature even after 30 minutes (Figure 5-7). It is to be noted that in the actual device, the 
dissolution time is much shorter at 10 minutes, most likely due to the shear of the constant flow 
rate. 
 
Figure 5-7 Fluorescence microscopy images of polymer-GO films incubated with FSE dye. Left: before and right: after being 
dipped in either cold (5°C) or room temperature (20°C) water for the specified time durations. Scale bar: 200 μm (3). 
5.4.2.3 Device performance characterization 
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To verify the steps of the conjugation chemistry, experiments were performed to compare 
capture by (1) a polymer film lacking GO alone; (2) a polymer film lacking GO with the addition 
of anti-EpCAM; and (3) the polymer-GO film with full conjugation chemistry. The two control 
films showed significantly lower levels of capture with the polymer film and the polymer film with 
antibody capturing at 6.4% and 11.0% the level of the full chemistry, respectively (Figure 5-8a), 
with the increase in capture of the polymer with antibody condition a likely a result of physically 
adsorbed anti-EpCAM. This also suggests that very little of the capture antibody on the fully 
functional device is non-specifically bound. 
 
To test the performance of the GO-polymer device for CTC capture, fluorescence labeled 
human breast cancer cell line MCF-7 cells (1,000 cells/mL) were spiked into buffer and flowed 
Figure 5-8 Device performance characterization. a) Capture efficiency of microfluidic devices featuring only the thermo-
sensitive polymer, the thermo-sensitive polymer and non-specifically bound anti-EpCAM, and the polymer-GO film with 
specific conjugation chemistry as normalized by this last condition. b) Cell capture efficiency of the microfluidic polymer-
GO device at various flow rates evaluated using a breast cancer cell line (MCF-7). Error bars show standard deviations 
(n=6). c) Capture efficiency of cell lines of varying origin and EpCAM expression levels. MCF-7 (n=8), PANC1, H1650, 
LNCaP, Hs578T (n=6). d) Release efficiency of the microfluidic polymer-GO device (MCF-7 cells were spiked into 1 mL of 
buffer or blood). e) Fluorescence microscope images of devices after capture and release of fluorescently-labeled MCF-7 
cells (3). 
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through the GO-polymer device at different flow rates (1-10 mL/hr). The captured cells in the 
device and the non-captured cells collected in the waste were then counted. As expected, the 
capture efficiency decreased with flow rate. The capture efficiency rapidly decreased at flow rates 
greater than 5 mL/hr. In the 1–3 mL/hr range, the average capture efficiency was over 88.2% (n = 
6 at each flow rate) with the highest capture of 95.21% at 1mL/hr (Figure 5-8b). To further 
investigate the effect of tumor type and EpCAM expression on capture efficiency, three high 
EpCAM expressing cell lines for various cancer types (MCF-7 breast cancer cells, LNCaP prostate 
cancer cells, and H1650 lung cancer cells), one low EpCAM expressing cancer-cell line (Panc-1 
pancreatic cancer cells), and one EpCAM negative cancer cell line (Hs578T breast cancer cells) 
were selected for capture experiments at the flow rate of 1 mL/hr. The cells were fluorescently 
labeled and spiked into buffer at a concentration of 1000 cells/ml. The results indicate that the anti-
EpCAM-coated GO-polymer device achieved high capture efficiency (84.93-95.21%) for 
EpCAM-positive cancer cells (Figure 5-8c). In contrast, a relatively low number of EpCAM-
negative cells (Hs578T) were captured. Furthermore, the device is comparably effective in 
capturing different tumor cells, indicating the robust sensitivity of the device.  After capturing cells 
on the devices, cell release experiments were carried out by flowing 1 mL cold PBS through 
devices cooled in ice at 100 μL/min (Figure 5-8e). Quantification of the cells in the devices before 
and after release showed an average cell release of 95.21% and 91.56% in buffer and blood 
experiments, respectively (Figure 5-8d). Furthermore, we tested the viability of the released cells 
by live dead assay. 91.68% of cells remained viable after release (Table 5-3). 
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Table 5-3 Experimental results from Live/Dead assay (MCF-7 cell line) (3). 
Device Live cells after release Dead cells after release Live/Dead (%) 
D1 264 22 92.31 
D2 353 7 98.06 
D3 174 10 94.57 
D4 270 35 88.52 
D5 152 27 84.92 
Average 91.68 
 
5.4.2.4 Clinical sample processing 
To demonstrate the potential for CTC capture and release in clincial samples using the 
tunable polymer-GO composite film based device, blood samples obtained from 10 metastatic 
breast cancer patients and three pancreatic cancer patients were processed. Whole blood samples 
collected into EDTA tubes were processed at a flow rate of 1 mL/hr. Following a washing step, 
cells were released from the chip and deposited/spun onto glass slides by a cytospin centrifuge. 
CTCs in these samples were identified as DAPI-positive (shown in blue) nucleated cells staining 
positive for tumor markers (cytokeratin 7/8, shown in red) and negative for leukocyte markers 
(CD45, shown in green) (Figure 5-9a). CTCs were successfully recovered from 8 breast cancer 
patient samples and 2 pancreatic cancer patients (ranging from 2 to 20 CTCs/mL) (Figure 5-9b). 
The average number of CTCs recovered from breast samples was 5.6 CTCs/mL and from 
pancreatic samples was 8.3 CTCs/mL.  
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Released CTCs were viable and structurally intact, and hence could be readily investigated 
via standard clinical cytopathological and genetic testing. Here the feasibility of detecting HER2 
amplification by fluorescence in situ hybridization (FISH) was examined, revealing HER2 
amplification in one breast cancer patient (Figure 5-9c). One green signal indicates the presence 
of one copy of HER2, while one red signals indicates one copy of centromere 17 probe; the 
multiple green signals in the figure implied HER2 amplification. 
5.5 Discussion 
Initial attempts to fabricate a transparent CTC capture/release device centered around the 
technique of LbL. However, the inability to maintain high capture without retaining a high number 
of nonspecifically bound cells led to the pursuit of other avenues before entering the release phase 
of the project. 
In the follow-up work, a microfluidic device bottom substrate was coated with a composite 
film of functionalized GO dispersed in a matrix of thermoresponsive polymer with a lower critical 
solution temperature (LCST) of 13°C. Surface available functionalized GO provided anchors for 
attaching the CTC capture antibody while the polymer matrix provided temperature dependent 
modulation of capture or release functionality. The microfluidic assembly facilitated the 
processing of patient blood samples within a simple planar device. Drop-casting the polymer-GO 
Figure 5-9 Patient sample processing with the thermosensitive polymer-GO release device. a) Fluorescence images of CTCs from 
breast cancer patient sample. Nucleated cells (blue) staining positive for cytokeratin 7/8 (red) and negative for the white blood cell 
marker CD45 (green) were enumerated as CTCs. Scale bar = 10 μm. b) CTC enumeration results from 10 breast cancer patients 
and 3 pancreatic cancer patients. c) Fluorescence in situ hybridization (FISH) image of CTCs of breast cancer patient sample 
Br10. HER2(green)/centromere 17 probe(red) (3). 
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blend on a patterned and surface modified substrate made such a device cheap and easy to 
fabricate. Moreover, the LCST of around 13°C for the polymer matrix made it possible to use the 
device at room temperature as opposed to higher temperatures (120), such that there were no 
concerns about inadvertently releasing the cells during the capture step. Additionally, cell release 
occurred under gentle conditions, maximizing the viability of released cells. The consolidation of 
the advantageous properties of GO-based capture with superior release functionality of the chosen 
polymer yielded a device that enables the study of these clinically interesting cells without many 
of the shortcomings of past technologies, while simultaneously presenting an easy, scalable 
fabrication method. 
The downstream analysis facilitated by the efficient release of captured cells highlights the 
potential for this device’s use in basic and clinical cancer investigation. As evidenced by data 
obtained from physiologic solutions containing spiked labeled cancer cells from multiple cancers 
and the processing of primary breast and pancreatic cancer patient blood samples, isolation of these 
rare cells with this device is highly feasible, completing the first step to unlocking the research 
opportunities presented by CTCs.  
Compared with other CTC isolation strategies, immunoaffinity based technologies harvest 
CTCs with high sensitivity and purity (267), but have the drawback of tethering cells within the 
device. Overcoming this limitation, the thermosensitive polymer-GO device collected viable and 
intact CTCs in suspension after immunocapture, making it ideal for various downstream analyses 
that require the high integrity and purity of the targeted cell population, such as genotyping and 
single cell profiling.  This advanced analysis of CTCs could become a “real-time” indicator to 
develop personalized therapy, as well as to bring valuable insights into the mechanism underlying 
cancer metastasis. Due to the low cost and ease of fabrication, this technology has the potential to 
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be scalable for commercialization. As the earlier GO based CTC isolation device, the GO Chip, 
featured high capture, low nonspecific binding, and reliable performance, upgrades to the device 
such that the new technology retains those characteristics while simultaneously enables high 
quality imaging and downstream analysis will continue to be the benchmark to which technology 
development aspires. 
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6.1 Research summary 
CTCs present the opportunity to further investigate the most devastating part of cancer – 
metastasis as propagated through those cells capable of traveling in the blood stream. To this end, 
the impetus for all research contained herein is motivated by the overarching aim of being able to 
better inform the patient. Through the study of both the biology of metastasis and the relation of 
these informative biomarkers to the trajectory of a specific patient’s disease, CTCs have the 
potential to inform the choices made in disease management. 
There remain unmet needs in the study and monitoring of genitourinary cancers, 
specifically those of the bladder and prostate. To address the need for an informative biomarker 
that provides more information than the PSA test, I present the alternative in circulating tumor 
cells, which, when isolated with the highly sensitive GO Chip technology, provided the options of 
investigating CTC counts, metrics related to CTC clusters, and RNA expression levels. In the 
second chapter of this thesis, I presented a pilot investigation into what prognostic information 
may be gleaned from mCRPC samples assayed in the form of whole blood processed across 
parallel GO Chips, one for enumeration and one for RNA extraction and analysis. CTCs were 
detected in all 41 samples processed for enumeration, with clusters presenting in 26/41 samples. 
This represents the highest percentage of prostate cancer patients in which CTC clusters have been 
detected. The parallel device was used to collect the cell lysate for RT-qPCR analysis. Gene 
expression levels were normalized to housekeeping genes and, with healthy control expression 
Chapter 6 Conclusion 
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levels subtracted, could be used to examine relative expression levels. With this information in 
hand, I could complete the bed to bench to bed cycle through the analysis of these enumeration 
metrics and RNA expression levels with respect to overall survival as well as clinical, PSA, and 
radiographic progression. Using the R programming language, I screened for genes that could be 
used to stratify patients into distinct prognostic categories to which I could ascribe a numeric score. 
By evaluating these scores in their different combinations, starting with those genes initially 
selected by their abilities to yield distinct groups as determined by a log rank p value calculated 
based on Kaplan-Meier analysis, I determined the combination of genes most prognostic as 
evaluated based on the area under the curve (AUC) from the resulting receiver operator 
characteristic curve (ROC) as well as the hazard ratio. The ultimate set of genes suggested the 
importance of a dedifferentiated phenotype in the prognosis of prostate cancer. 
In the third chapter of this dissertation, we investigated protein-level expression of specific 
molecular markers in prostate cancer. Overexpression of HER2 is a hallmark of breast cancer and 
is assessed based on gene amplification as determined through fluorescence in situ hybridization 
(FISH). However, HER2 gene amplification is not observed in prostate cancer. Our investigation 
into the protein level overexpression of HER2 in prostate cancer revealed overexpression in 
primary prostate cancer tissue microarrays relative to the healthy prostate; additionally, 
investigation of HER2 expression in bone metastases revealed overexpression relative to the 
primary tissue. Subsequent knockdowns of HER2 in the prostate cancer cell line C4-2B inhibited 
growth of these cells when injected into mouse tibia as assayed through expression of the 
proliferative marker Ki67. Investigation of tumor initiating capacity based on either the expression 
of HER2 or its fellow epidermal growth factor receptor family member EGFR showed that high 
HER2 expressing cells as determined by flow sorting did not have increased spheroid forming 
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capacity relative to low HER2 expressing cells; in contrast, high EGFR expressing cells has 
statistically significantly higher spheroid forming capacity for both primary and secondary 
prostaspheres. This led to questions about the role of EGFR in cell survival in circulation in 
addition to tumor initiating capacity. I probed this question by analyzing a small cohort of mCRPC 
patients to determine the presence of EGFR-expressing CTCs. I detected CTCs in all 10 patients 
with EGFR+ CTCs evident in 9/10 patients. Intrapatient heterogeneity was also apparent through 
the varied percentage of EGFR+ CTCs amongst patients (median: 35.5%). Given the potential 
complimentary roles of HER2 in tumor cell proliferation and EGFR in tumor initiation and 
survival in the blood stream, we investigated the administration of dual inhibitors and cocktails of 
monoclonal antibodies to treat prostate cancer in mouse models. In these animal models, tumors 
had significantly lower numbers of viable cells compared with those animals treated with therapies 
specifically targeted against HER2/EGFR. 
The ability to apply epidermal growth factor receptor family targeting drugs as well as 
therapies directed against additional targets was the impetus into our study of bladder cancer. In 
chapter four of this dissertation, I sought to apply the highly sensitive GO Chip to CTC isolation 
in bladder cancer, where previous investigations of CTCs were hampered by methodology, in this 
case the exclusive use of the CellSearch technology. Through the sensitive detection of bladder 
cancer CTCs through microfluidics and nanotechnology, I would have improved chances of 
investigating molecular markers of interest, specifically HER2 and EGFR as well as ADAM15 
and CD31. These two pairs of markers have implications as far as available treatments and the 
mechanisms of metastasis. Because of the limited investigation into bladder cancer CTCs, I spent 
increased energy on developing the combination of antibodies for capture, as assayed through cell 
spike experiments, and primary and secondary antibodies used in detection. Two combinations of 
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antibodies were ultimately used to stain five metastatic bladder cancer patient samples. CTCs were 
detected in all five patients (range: 5-499 CTCs/mL), with detection above a threshold as 
determined using a healthy control occurring on 9/10 devices processed. Additionally, we were 
able to visualize the results on-chip, in contrast to PCR based methods sometimes used for bladder 
cancer CTCs, such that we were able to observe cell clusters ranging from 2-39 CTCs/cluster. 
Using an optimized combination of antibodies, I detected EGFR and CD31 on some of the CTCs, 
providing insight into how these cells spread.  
While the GO Chip technology enabled the study of the presence of CTCs and CTC 
clusters; specific protein expression by those cells; and relative RNA expression levels by the bulk 
population captured on-chip, the full potential of CTCs may be better realized through further 
genetic characterization and other characterization at the single cell level. This will be best 
facilitated by the release of captured cells from the chip for subsequent analysis. To improve the 
current technology to enable this capability, I investigated two strategies for cell release. My initial 
studies involved the formation of a polymer substrate through Layer-by-Layer (LbL) deposition; 
this film could then be degraded by applying specific enzymes to degrade the film. Efforts included 
several polymer combinations with both ionic and van der Waals forces contributing to film 
formation. Films were ultimately enclosed in a polydimethylsiloxane (PDMS) chamber through 
irreversible corona discharge bonding. However, cell spikes in blood revealed difficulty in 
achieving a balance of two important CTC capture technology metrics: capture efficiency and 
purity. While the GO-PEG/PDDA device enabled high capture efficiency, too many white blood 
cells nonspecifically bound for the chip to be useful. Conversely, on the GO-TBA-
PEG/NaHyaluronate devices, nonspecific binding of white blood cells was negligible. 
Unfortunately, so was the capture efficiency. 
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Fruitless troubleshooting efforts yielded a shift to an alternative release strategy. While the 
use of thermosensitive polymers for CTC release had been previously established, hindrances such 
as inconvenient processing temperatures or involved chemical processes has impeded convenient 
use in the clinical setting. Our strategy made use of a tunable copolymer, whose lower critical 
solution temperature (LCST) could be modulated by varying the ratio of its component parts, DEA 
and AP. As verified through cell spikes, the microfluidic device fabricated by enclosing a dropcast 
GO-TBA-PEG/polymer composite could serve as the basis for the same functionalization 
chemistry as the GO Chip, enabling highly efficient capture (greater than 84% across EpCAM-
expressing cell lines). By cooling the device to approximately 4° C by placing it on ice and flowing 
chilled PBS, greater than 90% release was achieved in both buffer and whole blood. To verify 
clinical utility, we processed 10 breast and 3 pancreatic patient samples, detecting CTCs following 
the release step in 8/10 breast cancer patients and 2/3 pancreatic patient patients. We demonstrated 
proof-of-principle downstream analysis by performing HER2 FISH on CTCs captured from one 
breast cancer patient, revealing amplification. 
6.2 Limitations and future directions 
While the projects described above show great promise with regards to applying the 
aforementioned technologies to CTC isolation from patient samples, to more broadly apply such 
technologies and to generate data that would create true clinical impact, some limitations will need 
to be addressed. 
In examining RNA expression levels, I determined an eight-gene signature associated with 
shorter overall survival. However, this result was based solely on a small training cohort, and will 
need to be validated with an adequately powered testing cohort. Additionally, the GO Chip based 
CTC analysis had thus far has been conducted in a metastatic cohort, but some of the greatest 
 128 
 
opportunities in affecting change to patient treatment are in early stage and high risk patients. 
CTCs could be investigated as a prognostic biomarker for these patients with the goal of averting 
unnecessary surgery or therapeutics accompanied by harmful side effects. The current gene score 
could be tested in this cohort using the same techniques. Alternatively, a similar study to that in 
Chapter 2 could be conducted to identify markers that are more significant in earlier stage patients. 
Given the mounting evidence of the importance of stemlike cells in disease progression, detecting 
these markers in CTCs could provide clinicians and patients with the information they need to 
decide how aggressively to pursue treatment. 
To draw significant clinical conclusions, future studies will need to move past the 
exploratory phase to asking specific questions and selecting the specific cohort to answer those 
questions. Cohorts considered in this work were selected mainly based on availability, and while 
all patients had metastatic disease, treatment regimens and clinical characteristics were diverse, 
though not in a distribution that enabled meaningful comparison. Future work should involve 
cohort selection for specific characteristics based on the research question and of a size large 
enough to generate more robust conclusions. 
To facilitate the generation of larger cohorts, bottlenecks in sample processing need to be 
addressed. All microfluidic devices are currently fabricated in-house. Subsequent large scale 
studies would benefit from readily available devices produced more consistently than by our 
current small batch protocol. The biggest hurdle to the commercial production of this chip, as 
discovered through our limited collaboration with the Coulter Translational Research Partnership 
Program, is the chamber. Because the silicon substrate is produced using conventional microchip 
fabrication techniques, generating that component at scale would likely be feasible. However, there 
are many requirements of the PDMS chamber that prove difficult to fulfill. PDMS is more suited 
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to prototyping rather than large scale production (268), but whatever material we would use for 
large scale production would have to retain the optical transparency of PDMS (and possibly 
improve upon its tendency to autofluoresce) even once machined or molded with the 50 μm-height 
channel. While injection molding would solve the problems associated with machining, an 
injection mold is expensive, leading to apprehension in using them for prototypes, without which 
a design cannot be finalized. However, as it is now possible to 3D print injection molds (269), the 
price has dropped precipitously. This would allow for the large-scale production of chambers 
fabricated from an optically transparent material that can be corona discharge bonded to the silicon 
substrate, including various thermoplastic polymers (46). 
Other limitations to large-scale sample processing are related to the time lag associated 
with sample throughput and the staining/imaging/analysis workflow. A device redesign 
incorporating radial flow would improve throughput, as has been previously described (270), while 
ideally retaining the high sensitivity and purity of the original GO Chip. This is an investigation 
currently in progress in the lab.  Imaging and analysis roadblocks may be eased by upgrading our 
current microscope system and making use of automated image analysis, training software to 
conduct a preliminary pass on collected image using our wealth of CTC images, to find the location 
of these cells on-chip, and to take higher magnification images.  
Beyond the current patient sample processing paradigm, limitations to downstream 
analysis result in part from the fact that the captured cells remain tethered to the chip. While we 
have developed a thermosensitive polymer-GO release chip (Chapter 5, (3)), subsequent work with 
that device suffered from issues of reliability, so future directions in downstream analysis may 
need to be preceded by the development of new release strategies. To minimize changes to an 
already relatively successful technology, one strategy would be to shift the focus of the release 
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mechanism from the point at which the capture conjugation chemistry is tethered to the chip to the 
point where the antibody is tethered to the avidin. In chromatography, a conceptually similar 
technique involves exploiting the affinity of avidin with its binding partners (271). Desthiobiotin 
(DBS) was developed as a moiety that binds with avidin with lower affinity than biotin such that 
it may be ultimately displaced by a biotin solution. This approach has been used recently to release 
captured exosomes (272) and could be adapted to the release of captured CTCs. To do so, a DSB-
conjugated antibody, such as anti-EpCAM, would be introduced to the chip at the point where we 
currently use a biotinylated antibody. Following cell capture, cells could be eluted from the chip 
using a biotin solution. 
Even upon the advent of a mass produced high-throughput GO Chip with release enable, 
an additional challenge is that CTCs provide a limited amount of biological material to study and 
yet have the potential to provide a great deal of information should we be able to best use it. One 
way to maximize our ability to collect data from CTCs would be to expand day 0 CTCs in culture. 
Culture of CTCs has been previously attempted, but has previously been limited to cell line cell 
spike experiments (88) and CTCs isolated from animal models (273) or has featured issues with 
repeatability (274) and proliferation beyond the maintenance of the initial cell number (75). Some 
limited success occurred in the case of colon cancer where CTCs isolated using RosetteSep from 
two patients were cultured successfully for two months (275). However, both samples were taken 
from patients with greater than 300 CTCs/7.5 mL blood, and one of the cultures died off after the 
two-month period. There are multiple examples of CTC culture from breast cancer patient samples. 
CTCs isolated using fluorescence activated cell sorting (FACS) for “brain metastasis selected 
markers” were successfully cultured in three out of eight samples, allowing further examination in 
mouse xenograft models (276). The CTC-iChip has been used to culture breast cancer CTCs with 
 131 
 
a success rate of 6/36. A subsequent study also using the iChip studied HER2+ and HER2- 
populations in CTCs cultured from three breast cancer patients. In prostate cancer, CTC culture 
has been conducted with CTCs isolated by the filtration device MetaCell; however, while 64.3% 
of cultures were successful from patients with detectable CTCs, CTCs were only detected in 52% 
of prostate cancer patients assayed (277). Three dimensional organoid culture techniques (278) 
have been used to culture biopsies taken from metastases from advanced prostate cancer patients, 
including blood samples yielding greater than 100 CTCs per 10 mL blood (279), however culture 
was only demonstrated successfully for one blood sample. A promising method for CTC expansion 
has been demonstrated by our group using a coculture model with early stage lung cancer 
circulating tumor cells both isolated with and proliferated on a microfluidic platform (122). 
To enable CTC culture, a higher amount of “starting material,” i.e. day 0 CTCs, would be 
desirable, and may be enabled by high throughput processing of greater sample volumes. For each 
of the above culture strategies, optimization of several factors was necessary to achieve even 
modest success, with the composition of the cell culture media, presence of coculture cells, 
hypoxic conditions, adherent or nonadherent surfaces, and application of extracellular matrix 
proteins all serving as variable parameters. This suggests that attempts of genitourinary cancer 
CTC culture will require multiple informed choices of conditions. However, given that Matrigel 
is a near constant in the prior establishment of prostate cell lines suggests that it is a requirement, 
while the complications introduced by the use of coculture cells suggest that they should be 
avoided. 
Both high sensitivity capture of CTCs and their subsequent culture of captured CTCs could 
enable additional downstream genetic analysis for both personalized medicine and biological 
study. Prostate CTCs have already been examined for the androgen receptor splice variant 7 (AR-
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V7), which has been associated with resistance to enzalutamide and abiraterone (155). A follow 
up study found that men with the splice variant had a better response to taxanes than AR targeted 
therapies (280), showing the promise of CTCs in assisting clinical decisions. Future work on 
prostate cancer genetics may look at the different genetic directions the cancer may take through 
sampling and analyzing early stage patients. Mutations in SPOP have been found to be mutually 
exclusive with ETS gene fusions (281), with other exclusive mutations suggesting different disease 
mechanisms. Knowledge of different genetic aberrations could inform treatment selection, such as 
the use of PARP inhibitors in the case of ETS fusion positive patient or PI3K inhibitors in the case 
of amplification along that pathway (282). Sampling from the blood selects those cancer cells that 
have already completed the first steps of metastasis, and may therefore feature the genetic 
characteristic representative of the advancing disease. Similarly, the study of capture and/or 
cultured bladder cells may in the short term prevent the understaging of the disease and in the long 
term elucidate potential therapeutic targets. 
Metastasis is at the root of over 90% of cancer death, but through the collaboration of 
biologists, clinicians, and engineers, we possess the skills to optimize and improve current 
technology to conduct the studies necessary to study the weaknesses of this disease. Through the 
analysis of those cells responsible for disease spread, we have shown our ability to learn about the 
molecular markers involved and the trajectory of the disease, and further study will contribute to 
illuminating a molecular picture. 
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